CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
10629061,106290612,2,F,2014,20141112,20141205,20161201,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-21601083,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20161201,,CN,US,US,SUSTIVA,Erythema;Scratch,,,,,,,,,,,106290612,1,HIV test
11111546,111115462,2,F,,20161122,20150514,20161206,EXP,,FR-CIPLA LTD.-2015FR03693,CIPLA,,,,,,Y,,,20161206,,OT,PL,FR,Efavirenz,Burkitt's lymphoma,111115462,DE,,,,,,,,,111115462,1,HIV infection
11307801,113078019,9,F,,20161219,20150724,20161222,EXP,,DE-ROCHE-1495718,ROCHE,". ERRATUM: DACLATASVIR PLUS SOFOSBUVIR, WITH OR WITHOUT RIBAVIRIN, ACHIEVED HIGH SUSTAINED VIROLOGICAL RESPONSE RATES IN PATIENTS WITH HCV INFECTION AND ADVANCED LIVER DISEASE IN A REAL-WORLD COHORT. GUT 2016 DEC 01;65 (12):2060-.",,,,,Y,,,20161223,,MD,DE,DE,EFAVIRENZ,Abdominal pain;Acute kidney injury;Anaemia;Anal cancer;Arthralgia;Calculus urinary;Circulatory collapse;Clostridium difficile colitis;Dehydration;Diarrhoea;Drug withdrawal syndrome;Dyspnoea;Erysipelas;Fatigue;Fluid overload;Gastrointestinal infection;General physical health deterioration;Haemorrhoidal haemorrhage;Headache;Hepatic encephalopathy;Hepatic failure;Hepatocellular carcinoma;Hypersensitivity vasculitis;Hypertension;Hyponatraemia;Infection;Lactic acidosis;Liver disorder;Lymphoedema;Multiple organ dysfunction syndrome;Myocardial infarction;Nausea;Neutropenia;Pancreatitis acute;Pancytopenia;Peritonitis bacterial;Portal vein thrombosis;Soft tissue infection;Somnolence;Streptococcal sepsis;Vertigo,113078019,DE,,,,,,,,,113078019,1,Chronic hepatitis C
11550264,115502644,4,F,20150622,20161102,20150924,20161107,EXP,,ZA-GILEAD-2015-0173671,GILEAD,,31,YR,A,F,Y,38,KG,20161107,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood alkaline phosphatase increased;Diarrhoea;Gamma-glutamyltransferase increased,115502644,OT,,,115502644,1,201505,,,,115502644,1,HIV infection
11814242,118142422,2,F,20140806,20161227,20151209,20161229,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-21301353,BRISTOL MYERS SQUIBB,,36,YR,,M,Y,60.5,KG,20161229,,CN,US,UG,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Abdominal pain upper;Aspartate aminotransferase increased;Pancreatitis;Thrombocytopenia;Vomiting,118142422,HO,,,118142422,1,20140328,20150919,,,118142422,1,Kaposi's sarcoma AIDS related
11996013,119960133,3,F,20160106,20161003,20160203,20161007,EXP,,BR-GILEAD-2016-0194835,GILEAD,,28,YR,A,M,Y,60,KG,20161007,,MD,BR,BR,EFAVIRENZ,Nephrolithiasis,119960133,OT,,,119960133,1,20130507,,,,119960133,1,HIV infection
12188434,121884348,8,F,20160229,20161118,20160317,20161125,EXP,,ZW-GILEAD-2016-0203612,GILEAD,,39,YR,A,M,Y,61.5,KG,20161125,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Alopecia;Anaemia;Gastroenteritis;Hyponatraemia;Tuberculosis;Weight decreased,121884348,OT,,,121884348,1,20160219,20160228,,,121884348,1,Kaposi's sarcoma AIDS related
12215305,122153053,3,F,20150707,20161128,20160328,20161130,EXP,,ZA-BMSGILMSD-2016-0205223,GILEAD,,26,YR,A,F,Y,,,20161130,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,122153053,OT,,,122153053,1,20150302,,,,122153053,1,HIV infection
12357192,123571922,2,F,20150503,20161115,20160511,20161124,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-036449,BRISTOL MYERS SQUIBB,,50,YR,,M,Y,,,20161124,,CN,FR,FR,SUSTIVA,Arthralgia;CREST syndrome;Portal hypertension,123571922,OT,,,123571922,1,20060216,20160112,,,123571922,1,HIV infection
12381322,123813223,3,F,20150503,20161107,20160518,20161111,EXP,FR-AFSSAPS-TO20160894,FR-VIIV HEALTHCARE LIMITED-FR2016GSK067139,VIIV,,50,YR,,M,Y,,,20161111,,OT,FR,FR,SUSTIVA,Arthralgia;Scleroderma,123813223,OT,,,123813223,1,20060216,20160112,,,123813223,1,HIV infection
12381742,123817423,3,F,20150503,20161107,20160518,20161111,EXP,FR-AFSSAPS-TO20160894,FR-GLAXOSMITHKLINE-FR2016GSK067139,GLAXOSMITHKLINE,,50,YR,,M,Y,,,20161111,,OT,FR,FR,SUSTIVA,Arthralgia;Scleroderma,123817423,OT,,,123817423,1,20060216,20160112,,,123817423,1,HIV infection
12528907,125289073,3,F,20160421,20161103,20160705,20161109,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-034189,BRISTOL MYERS SQUIBB,,36,YR,,M,Y,60,KG,20161109,,CN,US,UG,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Encephalitis;Neutropenia,125289073,HO,,,125289073,1,20151021,20160329,,,125289073,1,Acquired immunodeficiency syndrome
12530583,125305832,2,F,20160928,20160928,20160706,20161003,PER,,US-GLAXOSMITHKLINE-US2016090263,GLAXOSMITHKLINE,,59,YR,,F,Y,,,20161003,,CN,US,US,SUSTIVA,Anaemia;Burning sensation;Drug screen positive,,,,,125305832,2,201606,,,,125305832,1,Product used for unknown indication
12531019,125310192,2,F,20160928,20160928,20160706,20161003,PER,,US-VIIV HEALTHCARE LIMITED-US2016090263,VIIV,,59,YR,,F,Y,,,20161003,,CN,US,US,SUSTIVA,Anaemia;Burning sensation;Drug screen positive,,,,,125310192,2,201606,,,,125310192,1,Product used for unknown indication
12538343,125383433,3,F,20150611,20160928,20160707,20161004,EXP,,CN-GILEAD-2016-0222113,GILEAD,,56,YR,A,M,Y,50,KG,20161004,,MD,CN,CN,EFAVIRENZ,Blood creatinine increased;Renal disorder,125383433,OT,,,125383433,1,20150611,20150922,,,125383433,1,HIV infection
12571446,125714462,2,F,,20161121,20160719,20161125,EXP,,US-GILEAD-2016-0223728,GILEAD,,56,YR,A,F,Y,,,20161125,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hypersensitivity;Osteoporosis,125714462,OT,,,125714462,1,,200811,,,125714462,1,HIV infection
12601795,126017954,4,F,20160725,20161006,20160728,20161013,EXP,,LS-JNJFOC-20160723137,JANSSEN,,56,YR,A,M,Y,68,KG,20161013,,MD,LS,LS,EFAVIRENZ,Electrocardiogram QT prolonged;Hypokalaemia,126017954,HO,,,126017954,2,20160712,20160905,,,126017954,1,Tuberculosis
12627469,126274692,2,F,20160513,20161222,20160805,20161227,EXP,,AR-GILEAD-2016-0226029,GILEAD,,42,YR,A,M,Y,93,KG,20161227,,OT,AR,AR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Intervertebral disc protrusion,126274692,HO,,,126274692,1,20100713,,,,126274692,1,HIV infection
12658027,126580272,2,F,,20161026,20160816,20161104,EXP,,AT-GILEAD-2016-0228187,GILEAD,,,,,,Y,,,20161104,,MD,AT,AT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Nephropathy toxic,126580272,OT,,,,,,,,,126580272,1,HIV infection
12671717,126717174,4,F,20150129,20161122,20160822,20161130,EXP,,ZA-GLAXOSMITHKLINE-ZA2016JPN120644,GLAXOSMITHKLINE,,43,YR,,F,Y,,,20161130,,MD,ZA,ZA,EFAVIRENZ + LAMIVUDINE + TENOFOVIR DISOPROXIL FUMARATE;Efavirenz,Gamma-glutamyltransferase increased,126717174,OT,,,126717174,1,20110825,20150209,,,126717174,1,HIV infection
12671944,126719444,4,F,20150129,20161122,20160822,20161130,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2016JPN120644,VIIV,,43,YR,,F,Y,,,20161130,,MD,ZA,ZA,EFAVIRENZ + LAMIVUDINE + TENOFOVIR DISOPROXIL FUMARATE;Efavirenz,Gamma-glutamyltransferase increased,126719444,OT,,,126719444,1,20110825,20150209,,,126719444,1,HIV infection
12674277,126742774,4,F,20140501,20160926,20160822,20161005,EXP,,ZA-GILEAD-2016-0229726,GILEAD,,28,YR,A,F,Y,82,KG,20161005,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Caesarean section;Exposure during pregnancy;Normal newborn,126742774,OT,,,126742774,1,20140117,,,,126742774,1,HIV infection
12687626,126876266,6,F,20160802,20161007,20160825,20161014,EXP,,UG-GILEAD-2016-0227055,GILEAD,,37,YR,A,M,Y,49,KG,20161014,,OT,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Anaemia,126876266,LT,,,126876266,1,20140319,20160802,,,126876266,1,Kaposi's sarcoma AIDS related
12718240,127182405,5,F,201311,20161009,20160906,20161110,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2016GSK128526,VIIV,,26,YR,,F,Y,,,20161110,,MD,GB,GB,EFAVIRENZ,Acute hepatic failure;Coagulopathy;Diarrhoea;Drug-induced liver injury;Hepatic necrosis;Jaundice;Lethargy;Liver transplant;Nausea;Schistosomiasis liver;Transaminases increased,127182405,OT,,,127182405,1,20160122,20160421,,,127182405,1,Product used for unknown indication
12725557,127255572,2,F,20160927,20160927,20160908,20161004,EXP,,GB-BMSGILMSD-2016-0231608,GILEAD,,69,YR,E,M,Y,,,20161004,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death;Pleurisy,127255572,OT,,,,,,,,,127255572,1,Product used for unknown indication
12727841,127278412,2,F,20160314,20161122,20160909,20161130,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-073055,BRISTOL MYERS SQUIBB,,52,YR,,F,Y,66,KG,20161130,,CN,US,GB,EFAVIRENZ,Extradural abscess,127278412,LT,,,127278412,1,20100617,,,,127278412,1,HIV infection
12740396,127403962,2,F,20141006,20161006,20160913,20161010,EXP,,ZA-GILEAD-2016-0232652,GILEAD,,38,YR,A,F,Y,51.4,KG,20161010,,MD,ZA,ZA,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pulmonary tuberculosis;Subcutaneous abscess;Treatment failure;Viral mutation identified,127403962,DE,,,127403962,1,20141002,20141012,,,127403962,1,HIV infection
12741774,127417742,2,F,20141006,20161006,20160914,20161011,EXP,,ZA-GLAXOSMITHKLINE-ZA2016133781,GLAXOSMITHKLINE,,38,YR,,F,Y,51.4,KG,20161011,,MD,ZA,ZA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE;Efavirenz,Pulmonary tuberculosis;Subcutaneous abscess;Treatment failure;Viral mutation identified,127417742,OT,,,127417742,1,2013,20141012,,,127417742,1,HIV infection
12741891,127418912,2,F,20141006,20161006,20160914,20161011,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2016133781,VIIV,,38,YR,,F,Y,51.4,KG,20161011,,MD,ZA,ZA,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE;Efavirenz,Pulmonary tuberculosis;Subcutaneous abscess;Treatment failure;Viral mutation identified,127418912,OT,,,127418912,1,2013,20141012,,,127418912,1,HIV infection
12748818,127488182,2,F,20140429,20161006,20160915,20161011,EXP,,ZA-GILEAD-2016-0232499,GILEAD,,41,YR,A,M,Y,67.5,KG,20161011,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury,127488182,LT,,,127488182,1,20131104,20160508,,,127488182,1,HIV infection
12755111,127551112,2,F,20160503,20161213,20160916,20161216,EXP,,MZ-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-040754,BRISTOL MYERS SQUIBB,,18,YR,,F,Y,36,KG,20161216,,OT,MZ,MZ,EFAVIRENZ,Acute kidney injury;Anaemia,127551112,HO,,,127551112,1,20160406,20160912,,,127551112,1,HIV infection
12756380,127563802,2,F,20140801,20161012,20160916,20161019,EXP,,ZA-GILEAD-2016-0232533,GILEAD,,20,YR,A,M,Y,41,KG,20161019,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gastroenteritis;Malnutrition;Tuberculosis gastrointestinal,127563802,OT,,,127563802,1,20140731,,,,127563802,1,HIV infection
12756384,127563842,2,F,20141103,20161014,20160916,20161024,EXP,,ZA-GILEAD-2016-0232638,GILEAD,,32,YR,A,M,Y,,,20161024,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Immunosuppression;Pancytopenia;Vomiting,127563842,HO,,,127563842,2,20141023,,,,127563842,1,Product used for unknown indication
12759439,127594392,2,F,20141209,20161004,20160919,20161010,EXP,,ZA-GILEAD-2016-0232907,GILEAD,,37,YR,A,F,Y,,,20161010,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute psychosis,127594392,HO,,,127594392,1,20121130,,,,127594392,1,HIV infection
12761074,127610742,2,F,20160706,20160921,20160920,20161005,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-076083,BRISTOL MYERS SQUIBB,,29,YR,,F,Y,40,KG,20161005,,CN,CN,CN,EFAVIRENZ,Delirium,,,,,127610742,1,20160622,20160706,,,127610742,1,Acquired immunodeficiency syndrome
12770858,127708582,2,F,20160605,20161011,20160922,20161013,PER,,US-VIIV HEALTHCARE LIMITED-US2016137901,VIIV,,72,YR,,M,Y,85.26,KG,20161013,,CN,US,US,SUSTIVA,Chills;Drug hypersensitivity;Headache;Hyperhidrosis;Myalgia;Nausea;Pyrexia,,,,,127708582,1,20160516,20160613,,,127708582,1,HIV infection
12776854,127768542,2,F,2016,20161102,20160923,20161108,EXP,,US-ABBVIE-16K-163-1734199-00,ABBVIE,,,,,M,Y,,,20161108,,CN,US,US,SUSTIVA,Fatigue;Foot fracture;Injection site pruritus;Malaise;Rib fracture,127768542,OT,,,127768542,1,201602,201610,,,127768542,1,Crohn's disease
12780948,127809484,4,F,20160909,20161025,20160926,20161102,EXP,,MW-GILEAD-2016-0234387,GILEAD,,31,YR,A,M,Y,58,KG,20161102,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Immune reconstitution inflammatory syndrome associated tuberculosis,127809484,HO,,,127809484,1,20160728,20160908,,,127809484,1,Acquired immunodeficiency syndrome
12786177,127861772,2,F,20160828,20161019,20160927,20161028,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-078232,BRISTOL MYERS SQUIBB,,37,YR,,F,Y,66,KG,20161028,,OT,UG,UG,EFAVIRENZ,Abortion incomplete;Anaemia;Maternal exposure during pregnancy;Pyrexia;Transfusion,127861772,HO,,,127861772,1,20130603,,,,127861772,1,HIV infection
12786689,127866892,2,F,20160828,20161012,20160927,20161024,EXP,,MW-GILEAD-2016-0233550,GILEAD,,50,YR,A,M,Y,41.7,KG,20161024,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE;TENOFOVIR + LAMIVUDINE + EFAVIRENZ,Pulmonary tuberculosis,127866892,HO,,,127866892,1,20160816,20160816,,,127866892,1,Kaposi's sarcoma AIDS related
12795134,127951342,2,F,20151015,20160922,20160929,20161011,EXP,,ZA-GILEAD-2016-0229134,GILEAD,,29,YR,A,F,Y,96.6,KG,20161011,,MD,ZA,ZA,EFAVIRENZ;EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Caesarean section;Maternal exposure during pregnancy;Prolonged labour,127951342,OT,,,127951342,1,20120816,,,,127951342,1,HIV infection
12800684,128006841,1,I,,20160919,20161001,20161001,EXP,,GB-HETERO LABS LTD-1057897,HETERO,,25,YR,,M,Y,,,20161001,,MD,GB,GB,Efavirenz,Porphyria acute,128006841,HO,,,,,,,,,128006841,1,HIV infection
12801125,128011251,1,I,,20160919,20161003,20161003,EXP,,GR-CIPLA LTD.-2016GR18982,CIPLA,,,,,,Y,,,20161003,,OT,FR,GR,Efavirenz,Acute kidney injury;Lactic acidosis,128011251,HO,,,,,,,,,128011251,1,HIV infection
12801144,128011441,1,I,,20160919,20161003,20161003,EXP,,US-CIPLA LTD.-2016US18986,CIPLA,,,,,,Y,,,20161003,,OT,FR,US,Efavirenz,Post infection glomerulonephritis;Renal tubular necrosis,128011441,OT,,,,,,,,,128011441,1,HIV infection
12801169,128011691,1,I,,20160919,20161003,20161003,EXP,,US-CIPLA LTD.-2016US18989,CIPLA,,,,,,Y,,,20161003,,OT,FR,US,Efavirenz,Intercapillary glomerulosclerosis;Tubulointerstitial nephritis,128011691,OT,,,,,,,,,128011691,1,HIV infection
12801175,128011751,1,I,,20160919,20161003,20161003,EXP,,US-CIPLA LTD.-2016US18996,CIPLA,,,,,,Y,,,20161003,,OT,FR,US,Efavirenz,Renal tubular necrosis,128011751,OT,,,,,,,,,128011751,1,HIV infection
12804079,128040791,1,I,20140123,20140129,20161003,20161003,EXP,,UG-GILEAD-2014-0093655,GILEAD,,35,YR,A,F,Y,38,KG,20161003,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Burning sensation;Diarrhoea;Hypokalaemia;Hyponatraemia;Malaise;Muscular weakness;Oedema peripheral;Pyrexia;Skin hyperpigmentation;Vomiting,128040791,HO,,,128040791,1,20121114,20140122,,,128040791,1,HIV infection
12804522,128045221,1,I,20130206,20160921,20161003,20161003,EXP,,ZA-GILEAD-2016-0235500,GILEAD,,1,DY,N,,Y,,,20161003,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Premature baby,128045221,DE,,,128045221,1,20121008,,,,128045221,1,HIV infection
12808467,128084671,1,I,2006,20160502,20161004,20161004,EXP,,US-DSJP-DSU-2016-115237,DAIICHI,,,,,,Y,,,20161004,,MD,US,US,SUSTIVA,Acute kidney injury;Colectomy;Colon adenoma;Intestinal obstruction;Malabsorption;Peritonitis,128084671,HO,,,128084671,1,2003,201205,,,128084671,1,Hypertension
12809802,128098021,1,I,20160826,20160929,20161005,20161005,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-082630,BRISTOL MYERS SQUIBB,,41,YR,,F,Y,116.2,KG,20161005,,CN,US,ZA,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Drug-induced liver injury,128098021,OT,,,128098021,1,201604,20160826,,,128098021,1,Back pain
12810571,128105711,1,I,,20160921,20161005,20161005,EXP,,CA-APOTEX-2016AP012493,APOTEX,,,,,M,Y,,,20161005,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,128105711,OT,,,,,,,,,128105711,1,Product used for unknown indication
12810583,128105831,1,I,20160913,20160920,20161005,20161005,EXP,,GB-MYLANLABS-2016M1042831,MYLAN,,,,,,Y,,,20161005,,CN,GB,GB,Efavirenz,Maternal exposure during pregnancy;Pre-eclampsia;Proteinuria;Urinary tract infection,128105831,OT,,,128105831,1,20160725,,,,128105831,1,Product used for unknown indication
12812571,128125712,2,F,20160809,20161017,20161005,20161019,EXP,,AR-ABBVIE-16P-007-1744542-00,ABBOTT,,51,YR,,M,Y,85,KG,20161019,,MD,AR,AR,EFAVIRENZ,Overdose,128125712,OT,,,128125712,1,20160216,,,,128125712,1,HIV infection
12815372,128153724,4,F,20160801,20161101,20161005,20161109,EXP,,UG-GILEAD-2016-0226992,GILEAD,,36,YR,A,M,Y,56,KG,20161109,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Encephalitis;Pulmonary embolism,128153724,HO,,,128153724,1,20151021,20160801,,,128153724,1,Acquired immunodeficiency syndrome
12817795,128177952,2,F,20160902,20161005,20161005,20161014,EXP,,FR-GILEAD-2016-0235829,GILEAD,,52,YR,A,M,Y,68,KG,20161014,,OT,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Rectal cancer,128177952,HO,,,128177952,1,20101105,,,,128177952,1,HIV infection
12817974,128179741,1,I,,20161003,20161005,20161005,EXP,,CA-BMSGILMSD-2016-0236549,GILEAD,,47,YR,A,F,Y,,,20161005,,PH,CA,CA,EFAVIRENZ,Metabolic acidosis,128179741,OT,,,,,,,,,128179741,1,Product used for unknown indication
12821338,128213381,1,I,20160604,20160928,20161006,20161006,EXP,,ZA-GILEAD-2016-0236100,GILEAD,,34,YR,A,F,Y,58,KG,20161006,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Ovarian cyst,128213381,HO,,,128213381,1,20150921,,,,128213381,1,HIV infection
12824077,128240771,1,I,20160715,20160928,20161006,20161006,EXP,,AU-GILEAD-2016-0235855,GILEAD,,31,YR,A,M,Y,78,KG,20161006,,MD,AU,AU,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Overdose;Suicide attempt,128240771,LT,,,128240771,1,20151015,,,,128240771,1,HIV infection
12825387,128253871,1,I,,20160929,20161006,20161006,EXP,,IT-GILEAD-2016-0236046,GILEAD,,67,YR,E,M,Y,87,KG,20161006,,MD,IT,IT,EFAVIRENZ,Chronic kidney disease;Toxicity to various agents,128253871,OT,,,128253871,1,20151022,,,,128253871,1,Antiretroviral therapy
12827933,128279331,1,I,20160819,20160825,20161007,20161007,EXP,,ZW-GILEAD-2016-0231301,GILEAD,,29,YR,A,M,Y,,,20161007,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kaposi's sarcoma,128279331,HO,,,128279331,1,20150702,20160818,,,128279331,1,Acquired immunodeficiency syndrome
12830781,128307811,1,I,20150413,20160920,20161007,20161007,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2016GSK146704,VIIV,,47,YR,,F,Y,,,20161007,,MD,ZA,ZA,Efavirenz,Anaemia,128307811,OT,,,128307811,1,20140611,,,,128307811,1,HIV infection
12830782,128307821,1,I,201504,20160920,20161007,20161007,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2016GSK146744,VIIV,,,,,M,Y,,,20161007,,MD,ZA,ZA,Efavirenz,Death,128307821,DE,,,128307821,1,20141125,20141125,,,128307821,1,HIV infection
12830783,128307831,1,I,20150913,20160920,20161007,20161007,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2016GSK146755,VIIV,,56,YR,,F,Y,,,20161007,,MD,ZA,ZA,Efavirenz,Diabetes mellitus inadequate control;Haematemesis,128307831,OT,,,128307831,1,20150217,20150913,,,128307831,1,HIV infection
12830784,128307841,1,I,201504,20160920,20161007,20161007,EXP,,ZA-GLAXOSMITHKLINE-ZA2016GSK146744,GLAXOSMITHKLINE,,,,,M,Y,,,20161007,,MD,ZA,ZA,Efavirenz,Death,128307841,DE,,,128307841,1,20141125,20141125,,,128307841,1,HIV infection
12830785,128307851,1,I,20150413,20160920,20161007,20161007,EXP,,ZA-GLAXOSMITHKLINE-ZA2016GSK146704,GLAXOSMITHKLINE,,47,YR,,F,Y,,,20161007,,MD,ZA,ZA,Efavirenz,Anaemia,128307851,OT,,,128307851,1,20140611,,,,128307851,1,HIV infection
12830786,128307861,1,I,20150913,20160920,20161007,20161007,EXP,,ZA-GLAXOSMITHKLINE-ZA2016GSK146755,GLAXOSMITHKLINE,,56,YR,,F,Y,,,20161007,,MD,ZA,ZA,Efavirenz,Diabetes mellitus inadequate control;Haematemesis,128307861,OT,,,128307861,1,20150217,20150913,,,128307861,1,HIV infection
12835330,128353301,1,I,,20161003,20161011,20161011,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-082927,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20161011,,OT,US,US,SUSTIVA,Hypersensitivity,,,,,,,,,,,128353301,1,Product used for unknown indication
12836982,128369821,1,I,20160818,20160929,20161011,20161011,EXP,,BR-MYLANLABS-2016M1043230,MYLAN,,,,,,Y,,,20161011,,CN,US,BR,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Foetal exposure during pregnancy;Stillbirth,128369821,DE,,,,,,,,,128369821,1,Product used for unknown indication
12837742,128377421,1,I,,20160930,20161012,20161012,EXP,,TZ-CIPLA LTD.-2016TZ19144,CIPLA,"SIKALENGO G, RAMIREZ A, FAINI D, MWAMELO K, BATTEGAY M, JUGHELI L ET AL.,. TUBERCULOUS SPONDYLITIS DIAGNOSED THROUGH XPERT MTB/RIF ASSAY IN URINE: A CASE REPORT. BMC INFECTIOUS DISEASES. 2016;16:514",,,,,Y,,,20161012,,OT,TZ,TZ,TENOFOVIR/LAMIVUDINE/EFAVIRENZ TABLET,Bone tuberculosis;Death;Treatment noncompliance,128377421,OT,,,128377421,1,2009,,,,128377421,1,HIV infection
12840571,128405711,1,I,,20161010,20161012,20161012,EXP,,ZW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-084893,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20161012,,OT,ZW,ZW,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Malignant neoplasm progression,128405711,OT,,,128405711,1,20140318,20140630,,,128405711,1,Kaposi's sarcoma AIDS related
12843715,128437151,1,I,,20161006,20161013,20161013,EXP,,TZ-SA-2016SA185331,AVENTIS,"SIKALENGO G, RAMIREZ A, FAINI D, MWAMELO K, BATTEGAY M, JUGHELI L, ET AL. TUBERCULOUS SPONDYLITIS DIAGNOSED THROUGH XPERT MTB/RIF ASSAY IN URINE: A CASE REPORT. BMC INFECT DIS. 2016;16:514. DOI: 10.1186/S12879-016-1844-0 ACCESSED ON: 2016 SEP 26",49,YR,A,M,Y,,,20161013,,OT,TZ,TZ,EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE,Bone tuberculosis;Disease progression;Inappropriate schedule of drug administration,128437151,OT,,,,,,,,,128437151,1,Bone tuberculosis
12845892,128458922,2,F,,20161010,20161013,20161020,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-083271,BRISTOL MYERS SQUIBB,,55,YR,,F,Y,,,20161020,,OT,IT,IT,EFAVIRENZ,Lipodystrophy acquired,128458922,OT,,,128458922,1,200412,200605,,,128458922,1,Antiretroviral therapy
12847189,128471891,1,I,2013,20151026,20161014,20161014,PER,,US-ABBVIE-15P-163-1493615-00,ABBOTT,,,,,M,Y,77.18,KG,20161014,,CN,US,US,Sustiva (NON-ABBVIE),Blood triglycerides increased;Nasopharyngitis;Oropharyngeal pain,,,,,128471891,1,2005,,,,128471891,1,HIV infection
12847862,128478622,2,F,201204,20161020,20161014,20161024,EXP,,RW-UCBSA-2016039514,UCB,,,,A,M,Y,,,20161024,,MD,RW,RW,Efavirenz,Drug dose omission;Generalised tonic-clonic seizure,128478622,DE,,,128478622,1,20120110,20120407,,,128478622,1,Partial seizures with secondary generalisation
12849112,128491122,2,F,,20161014,20161014,20161024,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-083217,BRISTOL MYERS SQUIBB,,,,,F,Y,2.74,KG,20161024,,CN,BR,BR,EFAVIRENZ,Foetal death;Foetal exposure during pregnancy,128491122,DE,,,128491122,1,20151128,20160818,,,128491122,1,Product used for unknown indication
12851865,128518651,1,I,,20161010,20161017,20161017,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-084929,BRISTOL MYERS SQUIBB,,50,YR,,M,Y,,,20161017,,CN,GB,IT,EFAVIRENZ,Lipodystrophy acquired,128518651,OT,,,,,,,,,128518651,1,HIV infection
12852249,128522491,1,I,,20161005,20161017,20161017,EXP,,BR-HETERO LABS LTD-1058406,HETERO,,27,YR,,F,Y,,,20161017,,OT,BR,BR,Efavirenz\ lamivudine \ Tenofovir  disoproxil fumarate,Exposure during pregnancy;Stillbirth,128522491,OT,,,128522491,1,20160412,,,,128522491,1,HIV infection
12852529,128525292,2,F,,20161026,20161017,20161103,EXP,,FR-ASTELLAS-2016US040318,ASTELLAS,,51,YR,,M,Y,,,20161103,,OT,FR,FR,EFAVIRENZ,BK virus infection;Donor specific antibody present;Graft complication;Histology abnormal;Neutropenia;Polyomavirus-associated nephropathy,128525292,OT,,,,,,,,,128525292,1,Renal transplant
12852628,128526281,1,I,,20161007,20161017,20161017,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-086102,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20161017,,MD,IT,IT,SUSTIVA,Neurotoxicity,128526281,OT,,,128526281,1,20110420,,,,128526281,1,HIV infection
12853703,128537031,1,I,20160818,20161005,20161017,20161017,EXP,,BR-CIPLA LTD.-2016BR19245,CIPLA,,,,,,Y,,,20161017,,OT,BR,BR,TENOFOVIR/LAMIVUDINE/EFAVIRENZ TABLET,Exposure during pregnancy;Stillbirth,128537031,OT,,,128537031,1,20140412,,,,128537031,1,HIV infection
12853730,128537301,1,I,,20161005,20161017,20161017,EXP,,BR-CIPLA LTD.-2016BR19246,CIPLA,,,,,,Y,,,20161017,,OT,BR,BR,TENOFOVIR/LAMIVUDINE/EFAVIRENZ TABLET,Anoxia;Foetal exposure during pregnancy;Stillbirth,128537301,DE,,,,,,,,,,,
12854418,128544181,1,I,,20161011,20161017,20161017,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-086083,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20161017,,CN,US,US,SUSTIVA,Fatigue,,,,,,,,,,,128544181,1,HIV infection
12854534,128545341,1,I,,20160929,20161017,20161017,EXP,,SG-GILEAD-2016-0235982,GILEAD,,,,,M,Y,,,20161017,,MD,SG,SG,EFAVIRENZ,Photosensitivity reaction,128545341,HO,,,,,,,,,128545341,1,Product used for unknown indication
12855270,128552702,2,F,20160910,20161021,20161017,20161102,EXP,,ZW-GILEAD-2016-0237389,GILEAD,,41,YR,A,M,Y,104.5,KG,20161102,,MD,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Lower limb fracture,128552702,HO,,,128552702,1,20140723,20141118,,,128552702,1,Kaposi's sarcoma AIDS related
12855273,128552732,2,F,20161003,20161014,20161017,20161025,EXP,,MW-GILEAD-2016-0237668,GILEAD,,25,YR,A,M,Y,,,20161025,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bacterial sepsis,128552732,HO,,,128552732,1,20160818,,,,128552732,1,Acquired immunodeficiency syndrome
12855851,128558511,1,I,,20161005,20161018,20161018,EXP,,US-CIPLA LTD.-2016US19338,CIPLA,,,,,,Y,,,20161018,,OT,US,US,Efavirenz,Adrenal suppression;Drug interaction,128558511,OT,,,,,,,,,128558511,1,HIV infection
12858261,128582611,1,I,20141216,20161009,20161018,20161018,EXP,,ZW-GILEAD-2016-0237882,GILEAD,,41,YR,A,F,Y,67.5,KG,20161018,,MD,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kaposi's sarcoma;Malignant neoplasm progression;Weight decreased,128582611,DE,,,128582611,1,20140318,20160118,,,128582611,1,Kaposi's sarcoma AIDS related
12859155,128591551,1,I,,20161004,20161018,20161018,EXP,,ZA-CMP PHARMA-2016CMP00034,CMP PHARMA,"STEAD DF, MASON CR. THREE CASES OF INTENTIONAL ISONIAZID OVERDOSE - A LIFE-THREATENING CONDITION.. S AFR MED J (DOI: 10.7196/SAMJ.2016.V106I9.10582). 2016;106:891-892",32,YR,,F,Y,,,20161018,,OT,ZA,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Acute kidney injury;Cardio-respiratory arrest;Intentional overdose;Toxicity to various agents,128591551,OT,,,,,,,,,128591551,1,Antibiotic prophylaxis
12859233,128592331,1,I,20160917,20161003,20161018,20161018,EXP,,ZW-GILEAD-2016-0238316,GILEAD,,60,YR,A,M,Y,61.2,KG,20161018,,MD,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kaposi's sarcoma,128592331,DE,,,128592331,1,20150529,20150911,,,128592331,1,Acquired immunodeficiency syndrome
12860709,128607095,5,F,20161004,20161117,20161019,20161123,EXP,,BR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-084891,BRISTOL MYERS SQUIBB,,24,YR,,F,Y,77,KG,20161123,,OT,BR,BR,EFAVIRENZ,Caesarean section;Gestational hypertension;Maternal exposure during pregnancy;Normal newborn;Suicidal ideation,128607095,OT,,,128607095,1,20160923,20161004,,,128607095,1,HIV infection
12862990,128629901,1,I,,20161004,20161019,20161019,EXP,,ZA-CMP PHARMA-2016CMP00035,CMP PHARMA,"STEAD DF, MASON CR. THREE CASES OF INTENTIONAL ISONIAZID OVERDOSE - A LIFE-THREATENING CONDITION. S AFR MED J (DOI: 10.7196/SAMJ.2016.V106I9.10582). 2016;106:891-892",52,YR,,F,Y,,,20161019,,OT,ZA,ZA,TENOFOVIR/EMTRICITABINE/EFAVIRENZ,Acute kidney injury;Intentional overdose;Rhabdomyolysis;Toxicity to various agents,128629901,HO,,,,,,,,,128629901,1,Antibiotic prophylaxis
12863669,128636691,1,I,,20161012,20161019,20161019,EXP,,GB-MYLANLABS-2016M1044109,MYLAN,,,,,,Y,,,20161019,,CN,GB,GB,EFAVIRENZ TABLETS 600MG,Activities of daily living impaired;Diarrhoea;Impaired work ability;Malaise;Product substitution issue,128636691,OT,,,,,,,,,128636691,1,Product used for unknown indication
12865163,128651631,1,I,,20161017,20161020,20161020,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2016GSK153318,VIIV,,,,,M,Y,50,KG,20161020,,OT,CN,CN,Efavirenz,Anaemia;Asthenia;Dizziness;Granulocytopenia;Headache;Liver injury;Syncope,128651631,HO,,,128651631,1,20160401,20160808,,,128651631,1,HIV infection
12866060,128660601,1,I,,20161017,20161020,20161020,EXP,,CN-GLAXOSMITHKLINE-CN2016GSK153318,GLAXOSMITHKLINE,,,,,M,Y,50,KG,20161020,,OT,CN,CN,Efavirenz,Anaemia;Asthenia;Dizziness;Granulocytopenia;Headache;Liver injury;Syncope,128660601,HO,,,128660601,1,20160401,20160808,,,128660601,1,HIV infection
12869205,128692051,1,I,200502,20161012,20161021,20161021,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2016154817,VIIV,,50,YR,,M,Y,,,20161021,,MD,GB,GB,Efavirenz,Treatment failure,128692051,OT,,,128692051,1,,200502,,,128692051,1,HIV infection
12870291,128702911,1,I,200502,20161012,20161021,20161021,EXP,,GB-GLAXOSMITHKLINE-GB2016154817,GLAXOSMITHKLINE,,50,YR,,M,Y,,,20161021,,MD,GB,GB,Efavirenz,Treatment failure,128702911,OT,,,128702911,1,,200502,,,128702911,1,HIV infection
12876845,128768453,3,F,201004,20161222,20161024,20161228,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2016JPN152007,VIIV,,49,YR,,F,Y,,,20161228,,MD,JP,JP,EFAVIRENZ,Chronic kidney disease;Diabetes mellitus;Hypertension;Lipids abnormal,128768453,OT,,,128768453,1,2009,20150202,,,128768453,1,HIV infection
12876846,128768462,2,F,,20161108,20161024,20161114,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2016JPN152009,VIIV,,65,YR,,F,Y,,,20161114,,MD,JP,JP,EFAVIRENZ,No adverse event,,,,,128768462,1,201212,201402,,,128768462,1,HIV infection
12876972,128769723,3,F,201004,20161222,20161024,20161228,EXP,,JP-GLAXOSMITHKLINE-JP2016JPN152007,GLAXOSMITHKLINE,,49,YR,,F,Y,,,20161228,,MD,JP,JP,EFAVIRENZ,Chronic kidney disease;Diabetes mellitus;Hypertension;Lipids abnormal,128769723,OT,,,128769723,1,2009,20150202,,,128769723,1,HIV infection
12878146,128781461,1,I,,20161015,20161024,20161024,EXP,,GB-GILEAD-2016-0239094,GILEAD,,54,YR,A,M,Y,,,20161024,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Blood cholesterol increased;Myocardial infarction;Renal impairment,128781461,OT,,,,,,,,,128781461,1,HIV infection
12878917,128789172,2,F,20160809,20161019,20161024,20161027,EXP,,CN-GILEAD-2016-0238925,GILEAD,,40,YR,A,M,Y,50,KG,20161027,,OT,CN,CN,EFAVIRENZ,Anaemia;Granulocytopenia;Liver injury,128789172,OT,,,128789172,1,20160401,20160808,,,128789172,1,HIV infection
12879418,128794182,2,F,20160809,20161108,20161025,20161116,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-089581,BRISTOL MYERS SQUIBB,,40,YR,,M,Y,50,KG,20161116,,CN,CN,CN,EFAVIRENZ,Anaemia;Granulocytopenia;Liver injury,128794182,HO,,,128794182,1,20160401,20160808,,,128794182,1,HIV infection
12880533,128805331,1,I,,20160929,20161025,20161025,EXP,,SG-VIIV HEALTHCARE LIMITED-SG2016GSK147609,VIIV,,,,,M,Y,,,20161025,,MD,SG,SG,EFAVIRENZ,Photosensitivity reaction,128805331,HO,,,,,,,,,128805331,1,Product used for unknown indication
12880578,128805781,1,I,,20160929,20161025,20161025,EXP,,SG-GLAXOSMITHKLINE-SG2016GSK147609,GLAXOSMITHKLINE,,,,,M,Y,,,20161025,,MD,SG,SG,EFAVIRENZ,Photosensitivity reaction,128805781,HO,,,,,,,,,128805781,1,Product used for unknown indication
12882282,128822821,1,I,20131112,20151111,20161025,20161025,EXP,,ZW-GILEAD-2015-0182701,GILEAD,,33,YR,A,M,Y,65.2,KG,20161025,,MD,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Weight decreased,128822821,OT,,,128822821,1,20130314,20131111,,,128822821,1,HIV infection
12883396,128833961,1,I,,20161018,20161025,20161025,EXP,,US-GILEAD-2016-0239556,GILEAD,,77,YR,E,M,Y,,,20161025,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident;Visual impairment,128833961,OT,,,,,,,,,128833961,1,HIV infection
12887669,128876691,1,I,,20161017,20161026,20161026,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-088494,BRISTOL MYERS SQUIBB,,66,YR,,M,Y,,,20161026,,OT,US,US,EFAVIRENZ,Retinal toxicity,128876691,OT,,,,,,,,,128876691,1,HIV infection
12887926,128879261,1,I,,20161017,20161027,20161027,EXP,,US-CIPLA LTD.-2016US19822,CIPLA,"FONG PS, FLYNN DM, EVANS CD, KORTHUIS PT. INTEGRASE STRAND TRANSFER INHIBITOR-ASSOCIATED DIABETES MELLITUS: A CASE REPORT. INT J STD AIDS. 2016",,,,,Y,,,20161027,,OT,US,US,Efavirenz,Diabetes mellitus,128879261,OT,,,,,,,,,,,
12888201,128882011,1,I,,20160929,20161027,20161027,EXP,,ZA-SUN PHARMACEUTICAL INDUSTRIES LTD-2016R1-125481,RANBAXY,"STEAD DF, MASON CR. THREE CASES OF INTENTIONAL ISONIAZID OVERDOSE - A LIFE-THREATENING CONDITION. S AFR MED J. 2016;SEP; 106(9):891-892",52,YR,,F,Y,,,20161027,,OT,ZA,ZA,Tenofovir/Emtricitabine/Efavirenz,Acute kidney injury;Intentional overdose;Seizure,128882011,LT,,,,,,,,,128882011,1,Prophylaxis
12888211,128882111,1,I,,20160929,20161027,20161027,EXP,,ZA-SUN PHARMACEUTICAL INDUSTRIES LTD-2016R1-125491,RANBAXY,"STEAD DF, MASON CR. THREE CASES OF INTENTIONAL ISONIAZID OVERDOSE - A LIFE-THREATENING CONDITION. S AFR MED J. 2016;SEP; 106(9):891-892",32,YR,,F,Y,,,20161027,,OT,ZA,ZA,TENOFOVIR/ EMTRICITABINE/ EFAVIRENZ,Cardio-respiratory arrest;Intentional overdose;Loss of consciousness;Status epilepticus,128882111,DE,,,,,,,,,128882111,1,Prophylaxis
12890258,128902581,1,I,,20161021,20161027,20161027,EXP,,US-GILEAD-2016-0239986,GILEAD,,55,YR,A,M,Y,,,20161027,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dizziness;Rheumatoid arthritis;Sciatic nerve injury,128902581,OT,,,128902581,1,20080101,,,,128902581,1,HIV infection
12891076,128910761,1,I,20051011,20161021,20161027,20161027,EXP,,GB-GILEAD-2016-0240193,GILEAD,,51,YR,A,M,Y,,,20161027,,MD,GB,GB,EFAVIRENZ,Herpes zoster;Secondary syphilis,128910761,OT,,,128910761,1,20030912,20051223,,,128910761,1,HIV infection
12891989,128919891,1,I,,20161018,20161028,20161028,EXP,,DE-CIPLA LTD.-2016GB20027,CIPLA,,,,,,Y,,,20161028,,OT,ES,DE,Efavirenz,Virologic failure,128919891,OT,,,,,,,,,128919891,1,HIV infection
12892001,128920011,1,I,,20161018,20161028,20161028,EXP,,DE-CIPLA LTD.-2016GB20031,CIPLA,,,,,,Y,,,20161028,,OT,ES,DE,Efavirenz,Virologic failure,128920011,OT,,,,,,,,,128920011,1,HIV infection
12892054,128920541,1,I,,20161018,20161028,20161028,EXP,,DE-CIPLA LTD.-2016GB20032,CIPLA,,,,,,Y,,,20161028,,OT,ES,DE,Efavirenz,Virologic failure,128920541,OT,,,,,,,,,128920541,1,HIV infection
12892070,128920701,1,I,,20161018,20161028,20161028,EXP,,DE-CIPLA LTD.-2016GB20033,CIPLA,,,,,,Y,,,20161028,,OT,ES,DE,Efavirenz,Virologic failure,128920701,OT,,,,,,,,,128920701,1,HIV infection
12892447,128924471,1,I,,20161018,20161028,20161028,EXP,,DE-CIPLA LTD.-2016GB20044,CIPLA,,,,,,Y,,,20161028,,OT,ES,DE,Efavirenz,Therapeutic response decreased,128924471,OT,,,,,,,,,128924471,1,HIV infection
12892490,128924901,1,I,,20161018,20161028,20161028,EXP,,DE-CIPLA LTD.-2016GB20034,CIPLA,,,,,,Y,,,20161028,,OT,ES,DE,Efavirenz,Therapeutic response decreased,128924901,OT,,,,,,,,,128924901,1,HIV infection
12892569,128925691,1,I,,20161018,20161028,20161028,EXP,,DE-CIPLA LTD.-2016GB20035,CIPLA,,,,,,Y,,,20161028,,OT,ES,DE,Efavirenz,Therapeutic response decreased,128925691,OT,,,,,,,,,128925691,1,HIV infection
12892591,128925911,1,I,,20161018,20161028,20161028,EXP,,DE-CIPLA LTD.-2016GB20043,CIPLA,,,,,,Y,,,20161028,,OT,ES,DE,Efavirenz,Disease progression,128925911,OT,,,,,,,,,128925911,1,HIV infection
12892660,128926601,1,I,,20161018,20161028,20161028,EXP,,GB-CIPLA LTD.-2016US20063,CIPLA,,,,,,Y,,,20161028,,OT,ES,GB,Efavirenz,Virologic failure,128926601,OT,,,,,,,,,128926601,1,HIV infection
12892681,128926811,1,I,,20161018,20161028,20161028,EXP,,GB-CIPLA LTD.-2016US20054,CIPLA,,,,,,Y,,,20161028,,OT,ES,GB,Efavirenz,Cardiac disorder,128926811,OT,,,,,,,,,128926811,1,HIV infection
12892723,128927231,1,I,,20161018,20161028,20161028,EXP,,GB-CIPLA LTD.-2016US20052,CIPLA,,,,,,Y,,,20161028,,OT,ES,GB,Efavirenz,Cardiac disorder,128927231,OT,,,,,,,,,128927231,1,HIV infection
12892738,128927381,1,I,,20161018,20161028,20161028,EXP,,GB-CIPLA LTD.-2016US20051,CIPLA,,,,,,Y,,,20161028,,OT,ES,GB,Efavirenz,Cardiac disorder,128927381,OT,,,,,,,,,128927381,1,HIV infection
12892744,128927441,1,I,,20161018,20161028,20161028,EXP,,GB-CIPLA LTD.-2016US20050,CIPLA,,,,,,Y,,,20161028,,OT,ES,GB,Efavirenz,Cardiac disorder,128927441,OT,,,,,,,,,128927441,1,HIV infection
12892747,128927471,1,I,,20161018,20161028,20161028,EXP,,GB-CIPLA LTD.-2016US20049,CIPLA,,,,,,Y,,,20161028,,OT,ES,GB,Efavirenz,Cardiac disorder,128927471,OT,,,,,,,,,128927471,1,HIV infection
12892805,128928051,1,I,,20161018,20161028,20161028,EXP,,DE-CIPLA LTD.-2016GB20047,CIPLA,,,,,,Y,,,20161028,,OT,ES,DE,Efavirenz,Therapeutic response decreased,128928051,OT,,,,,,,,,128928051,1,HIV infection
12892831,128928311,1,I,,20161018,20161028,20161028,EXP,,DE-CIPLA LTD.-2016GB20046,CIPLA,,,,,,Y,,,20161028,,OT,ES,DE,Efavirenz,Therapeutic response decreased,128928311,OT,,,,,,,,,128928311,1,HIV infection
12892896,128928961,1,I,,20161018,20161028,20161028,EXP,,GB-CIPLA LTD.-2016US20064,CIPLA,,,,,,Y,,,20161028,,OT,ES,GB,Efavirenz,Virologic failure,128928961,OT,,,,,,,,,128928961,1,HIV infection
12892903,128929031,1,I,,20161018,20161028,20161028,EXP,,GB-CIPLA LTD.-2016US20065,CIPLA,,,,,,Y,,,20161028,,OT,ES,GB,Efavirenz,Virologic failure,128929031,OT,,,,,,,,,128929031,1,HIV infection
12901850,129018501,1,I,,20161018,20161102,20161102,EXP,,GB-CIPLA LTD.-2016US20056,CIPLA,,,,,,Y,,,20161102,,OT,ES,GB,Efavirenz,Cardiac disorder,129018501,OT,,,,,,,,,129018501,1,HIV infection
12901876,129018761,1,I,,20161018,20161102,20161102,EXP,,GB-CIPLA LTD.-2016US20057,CIPLA,,,,,,Y,,,20161102,,OT,ES,GB,Efavirenz,Cardiac disorder,129018761,OT,,,,,,,,,129018761,1,HIV infection
12901926,129019261,1,I,,20161018,20161102,20161102,EXP,,GB-CIPLA LTD.-2016US20058,CIPLA,,,,,,Y,,,20161102,,OT,ES,GB,Efavirenz,Cardiac disorder,129019261,OT,,,,,,,,,129019261,1,HIV infection
12901928,129019281,1,I,,20161018,20161102,20161102,EXP,,GB-CIPLA LTD.-2016US20062,CIPLA,,,,,,Y,,,20161102,,OT,ES,GB,Efavirenz,Virologic failure,129019281,OT,,,,,,,,,129019281,1,HIV infection
12901936,129019361,1,I,,20161018,20161102,20161102,EXP,,GB-CIPLA LTD.-2016US20061,CIPLA,,,,,,Y,,,20161102,,OT,ES,GB,Efavirenz,Virologic failure,129019361,OT,,,,,,,,,129019361,1,HIV infection
12901944,129019441,1,I,,20161018,20161102,20161102,EXP,,GB-CIPLA LTD.-2016US20060,CIPLA,,,,,,Y,,,20161102,,OT,ES,GB,Efavirenz,Virologic failure,129019441,OT,,,,,,,,,129019441,1,HIV infection
12901945,129019451,1,I,,20161018,20161102,20161102,EXP,,GB-CIPLA LTD.-2016US20059,CIPLA,,,,,,Y,,,20161102,,OT,ES,GB,Efavirenz,Virologic failure,129019451,OT,,,,,,,,,129019451,1,HIV infection
12901977,129019771,1,I,,20161019,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20438,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129019771,OT,,,,,,,,,129019771,1,Prophylaxis against HIV infection
12901991,129019911,1,I,,20161019,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20440,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102,,OT,UG,US,Efavirenz,Drug resistance;Foetal exposure during pregnancy;Virologic failure,129019911,OT,,,,,,,,,129019911,1,Prophylaxis against HIV infection
12901994,129019941,1,I,,20161019,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20437,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129019941,OT,,,,,,,,,129019941,1,Prophylaxis against HIV infection
12901998,129019981,1,I,,20161019,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20439,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129019981,OT,,,,,,,,,129019981,1,Prophylaxis against HIV infection
12902048,129020481,1,I,,20161019,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20447,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129020481,OT,,,,,,,,,129020481,1,HIV infection
12902055,129020551,1,I,,20161019,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20448,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129020551,OT,,,,,,,,,129020551,1,HIV infection
12902058,129020581,1,I,,20161019,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20451,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129020581,OT,,,,,,,,,129020581,1,HIV infection
12902061,129020611,1,I,,20161019,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20443,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102,,OT,UG,LB,Efavirenz,Drug resistance;Virologic failure,129020611,OT,,,,,,,,,129020611,1,Prophylaxis against HIV infection
12902066,129020661,1,I,,20161019,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20449,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129020661,OT,,,,,,,,,129020661,1,HIV infection
12902070,129020701,1,I,,20161019,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20446,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129020701,OT,,,,,,,,,129020701,1,HIV infection
12902072,129020721,1,I,,20161019,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20452,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63(8):1113 TO 1121",,,,,Y,,,20161102,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129020721,OT,,,,,,,,,129020721,1,Prophylaxis against HIV infection
12902081,129020811,1,I,,20161019,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20450,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129020811,OT,,,,,,,,,129020811,1,HIV infection
12902089,129020891,1,I,,20161019,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20441,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129020891,OT,,,,,,,,,129020891,1,Prophylaxis against HIV infection
12902091,129020911,1,I,,20161019,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20444,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129020911,OT,,,,,,,,,129020911,1,HIV infection
12902097,129020971,1,I,,20161019,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20445,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129020971,OT,,,,,,,,,129020971,1,HIV infection
12902100,129021001,1,I,,20161019,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20442,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102,,OT,UG,LB,Efavirenz,Drug resistance;Virologic failure,129021001,OT,,,,,,,,,129021001,1,Prophylaxis against HIV infection
12902308,129023081,1,I,,20161019,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20456,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63 (8):1113 TO 1121",,,,,Y,,,20161102,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129023081,OT,,,,,,,,,129023081,1,Prophylaxis against HIV infection
12902339,129023391,1,I,,20161019,20161102,20161102,EXP,,US-CIPLA LTD.-2016LB20455,CIPLA,"BARLOW-MOSHA L, ANGELIDOU K, LINDSEY J, ARCHARY M, COTTON M, DITTMER S ET AL.,. NEVIRAPINE-VERSUS LOPINAVIR/RITONAVIR-BASED ANTIRETROVIRAL THERAPY IN HIV-INFECTED INFANTS AND YOUNG CHILDREN: LONG-TERM FOLLOW-UP OF THE IMPAACT P1060 RANDOMIZED TRIAL. CLINICAL INFECTIOUS DISEASES. 2016;63(8):1113 TO 1121",,,,,Y,,,20161102,,OT,UG,US,Efavirenz,Drug resistance;Virologic failure,129023391,OT,,,,,,,,,129023391,1,Prophylaxis against HIV infection
12903921,129039211,1,I,20131230,20140102,20161102,20161102,EXP,,MW-GILEAD-2014-0091377,GILEAD,,41,YR,A,M,Y,55.5,KG,20161102,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia;Bacterial sepsis,129039211,DE,,,129039211,1,20131111,20131229,,,129039211,1,HIV infection
12904155,129041551,1,I,,20161025,20161102,20161102,EXP,,US-GILEAD-2016-0240760,GILEAD,,55,YR,A,M,Y,,,20161102,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cardiac failure congestive,129041551,HO,,,,,,,,,129041551,1,HIV infection
12904289,129042894,4,F,,20161108,20161102,20161122,EXP,,GB-009507513-1611GBR000159,MERCK,,51,YR,,M,Y,,,20161122,,CN,GB,GB,SUSTIVA,Activities of daily living impaired;Diarrhoea;Malaise;Product substitution issue,129042894,OT,,,,,,,,,129042894,1,Product used for unknown indication
12904994,129049942,2,F,20161017,20161107,20161102,20161110,EXP,,UG-GILEAD-2016-0240974,GILEAD,,51,YR,A,F,Y,,,20161110,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia,129049942,LT,,,129049942,1,20131022,,,,129049942,1,HIV infection
12905005,129050051,1,I,201610,20161028,20161102,20161102,EXP,,GB-GILEAD-2016-0241105,GILEAD,,56,YR,A,F,Y,,,20161102,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Dehydration;Fall;Musculoskeletal disorder;Urinary tract infection,129050051,HO,,,,,,,,,129050051,1,Product used for unknown indication
12907642,129076422,2,F,,20161116,20161103,20161122,EXP,,GB-GILEAD-2016-0241219,GILEAD,,51,YR,A,M,Y,,,20161122,,CN,GB,GB,SUSTIVA,Activities of daily living impaired;Diarrhoea;Malaise;Product substitution issue,129076422,OT,,,,,,,,,129076422,1,Product used for unknown indication
12908657,129086571,1,I,20161009,20161028,20161103,20161103,EXP,,UG-GILEAD-2016-0241099,GILEAD,,54,YR,A,F,Y,79,KG,20161103,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Hepatic encephalopathy,129086571,OT,,,129086571,1,20160215,20160928,,,129086571,1,HIV infection
12908760,129087601,1,I,20160827,20160928,20161103,20161103,EXP,,AR-GILEAD-2016-0236084,GILEAD,,49,YR,A,M,Y,72,KG,20161103,,MD,AR,AR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Herpes zoster,129087601,HO,,,129087601,1,20131107,,,,129087601,1,HIV infection
12909513,129095131,1,I,,20140719,20161104,20161104,EXP,,TH-CIPLA LTD.-2016TH10034,CIPLA,"CRESSEY TR, STEK A, CAPPARELLI E, BOWONWATANUWONG C, PROMMAS S, SIRIVATANAPA AND ET AL.,. EFAVIRENZ PHARMACOKINETICS DURING THE THIRD TRIMESTER OF PREGNANCY AND POSTPARTUM. J ACQUIR IMMUNE DEFIC SYNDR. 2012;59(3):245 TO 252",,,,,Y,,,20161104,,OT,TH,TH,Efavirenz,Exposure during pregnancy;Premature labour;Premature rupture of membranes,129095131,OT,,,,,,,,,129095131,1,HIV infection
12909520,129095201,1,I,,20140719,20161104,20161104,EXP,,TH-CIPLA LTD.-2016TH10035,CIPLA,"CRESSEY TR, STEK A, CAPPARELLI E, BOWONWATANUWONG C, PROMMAS S, SIRIVATANAPA ET AL.. EFAVIRENZ PHARMACOKINETICS DURING THE THIRD TRIMESTER OF PREGNANCY AND POSTPARTUM. J ACQUIR IMMUNE DEFIC SYNDR. 2012;59(3):245 TO 252",,,,,Y,,,20161104,,OT,TH,TH,Efavirenz,Exposure during pregnancy;Gestational diabetes;Premature rupture of membranes,129095201,OT,,,,,,,,,129095201,1,HIV infection
12911257,129112571,1,I,,20140719,20161104,20161104,EXP,,TH-CIPLA LTD.-2016TH10032,CIPLA,"CRESSEY TR, STEK A, CAPPARELLI E, BOWONWATANUWONG C, PROMMAS S, SIRIVATANAPA P ET AL. EFAVIRENZ PHARMACOKINETICS DURING THE THIRD TRIMESTER OF PREGNANCY AND POSTPARTUM. J ACQUIR IMMUNE DEFIC SYNDR. 2012;59 (3):245 TO 252",,,,,Y,,,20161104,,OT,TH,TH,Efavirenz,Foetal exposure during pregnancy;Human immunodeficiency virus transmission,129112571,OT,,,,,,,,,129112571,5,Prophylaxis against HIV infection
12913682,129136821,1,I,,20161027,20161104,20161104,EXP,,RO-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-093597,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20161104,,OT,RO,RO,EFAVIRENZ,Blood cholesterol increased;Blood triglycerides increased;Irritability;Lipodystrophy acquired;Sleep disorder,129136821,OT,,,,,,,,,129136821,1,Antiretroviral therapy
12913810,129138101,1,I,20161005,20161031,20161104,20161104,EXP,,GB-GILEAD-2016-0241459,GILEAD,,56,YR,A,M,Y,66.4,KG,20161104,,MD,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Appendicitis perforated,129138101,HO,,,129138101,1,20110718,20161011,,,129138101,1,HIV infection
12913922,129139221,1,I,,20161027,20161104,20161104,EXP,,RO-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-093988,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20161104,,OT,RO,RO,EFAVIRENZ,Lipodystrophy acquired;Neuropathy peripheral;Nightmare;Sleep disorder,129139221,OT,,,,,,,,,129139221,1,Antiretroviral therapy
12913950,129139501,1,I,,20161024,20161104,20161104,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-089808,BRISTOL MYERS SQUIBB,,44,YR,,M,Y,,,20161104,,OT,US,US,EFAVIRENZ,Blood triglycerides increased;Insomnia,,,,,,,,,,,129139501,1,Product used for unknown indication
12922790,129227901,1,I,,20161028,20161109,20161109,EXP,,GH-CIPLA LTD.-2016GH20816,CIPLA,,,,,,Y,,,20161109,,OT,US,GH,Efavirenz,Adverse event,129227901,OT,,,,,,,,,129227901,1,HIV infection
12922809,129228091,1,I,,20161028,20161109,20161109,EXP,,GH-CIPLA LTD.-2016GH20820,CIPLA,,,,,,Y,,,20161109,,OT,US,GH,Efavirenz,Death,129228091,DE,,,,,,,,,129228091,1,HIV infection
12922817,129228171,1,I,,20161028,20161109,20161109,EXP,,GH-CIPLA LTD.-2016GH20818,CIPLA,,,,,,Y,,,20161109,,OT,US,GH,Efavirenz,Adverse event,129228171,OT,,,,,,,,,129228171,1,HIV infection
12922821,129228211,1,I,,20161028,20161109,20161109,EXP,,GH-CIPLA LTD.-2016GH20819,CIPLA,,,,,,Y,,,20161109,,OT,US,GH,Efavirenz,Death,129228211,DE,,,,,,,,,129228211,1,HIV infection
12922838,129228381,1,I,,20161028,20161109,20161109,EXP,,GH-CIPLA LTD.-2016GH20829,CIPLA,,,,,,Y,,,20161109,,OT,US,GH,Efavirenz,Treatment failure,129228381,OT,,,,,,,,,129228381,1,HIV infection
12922852,129228521,1,I,,20161028,20161109,20161109,EXP,,GH-CIPLA LTD.-2016GH20832,CIPLA,,,,,,Y,,,20161109,,OT,US,GH,Efavirenz,Treatment failure,129228521,OT,,,,,,,,,129228521,1,HIV infection
12922858,129228581,1,I,,20161028,20161109,20161109,EXP,,GH-CIPLA LTD.-2016GH20830,CIPLA,,,,,,Y,,,20161109,,OT,US,GH,Efavirenz,Treatment failure,129228581,OT,,,,,,,,,129228581,1,HIV infection
12922863,129228631,1,I,,20161028,20161109,20161109,EXP,,GH-CIPLA LTD.-2016GH20828,CIPLA,,,,,,Y,,,20161109,,OT,US,GH,Efavirenz,Treatment failure,129228631,OT,,,,,,,,,129228631,1,HIV infection
12922870,129228701,1,I,,20161028,20161109,20161109,EXP,,TZ-CIPLA LTD.-2016TZ20750,CIPLA,,,,,,Y,,,20161109,,OT,SE,TZ,Efavirenz,Death,129228701,DE,,,,,,,,,129228701,1,HIV infection
12922874,129228741,1,I,,20161028,20161109,20161109,EXP,,TZ-CIPLA LTD.-2016TZ20745,CIPLA,,,,,,Y,,,20161109,,OT,SE,TZ,Efavirenz,Drug-induced liver injury,129228741,DE,,,,,,,,,129228741,1,HIV infection
12922885,129228851,1,I,,20161028,20161109,20161109,EXP,,TZ-CIPLA LTD.-2016TZ20757,CIPLA,,,,,,Y,,,20161109,,OT,SE,TZ,Efavirenz,Death,129228851,DE,,,,,,,,,129228851,1,HIV infection
12922892,129228921,1,I,,20161028,20161109,20161109,EXP,,TZ-CIPLA LTD.-2016TZ20752,CIPLA,,,,,,Y,,,20161109,,OT,SE,TZ,Efavirenz,Death,129228921,DE,,,,,,,,,129228921,1,HIV infection
12922896,129228961,1,I,,20161028,20161109,20161109,EXP,,TZ-CIPLA LTD.-2016TZ20746,CIPLA,,,,,,Y,,,20161109,,OT,SE,TZ,Efavirenz,Drug-induced liver injury,129228961,DE,,,,,,,,,129228961,1,HIV infection
12922906,129229061,1,I,,20161028,20161109,20161109,EXP,,TZ-CIPLA LTD.-2016TZ20747,CIPLA,,,,,,Y,,,20161109,,OT,SE,TZ,Efavirenz,Drug-induced liver injury,129229061,DE,,,,,,,,,129229061,1,HIV infection
12922914,129229141,1,I,,20161028,20161109,20161109,EXP,,TZ-CIPLA LTD.-2016TZ20748,CIPLA,,,,,,Y,,,20161109,,OT,SE,TZ,Efavirenz,Drug-induced liver injury,129229141,DE,,,,,,,,,129229141,1,HIV infection
12922931,129229311,1,I,,20161027,20161109,20161109,EXP,,RO-MYLANLABS-2016M1047678,MYLAN,"NEGUT AC, STREINU-CERCEL O, LAZER M, STREINU-CERCEL A. LONG SURVIVOR FAMILY WITH HIV INFECTION. CASE PRESENTATION. BMC-INFECT-DIS 2013;13 (SUPPL. 1): ABSTR. P56.",,,,,Y,,,20161109,,OT,RO,RO,EFAVIRENZ,Lipodystrophy acquired;Neuropathy peripheral;Nightmare;Sleep disorder,129229311,OT,,,,,,,,,129229311,1,Antiretroviral therapy
12923773,129237731,1,I,20161108,,20161108,20161108,DIR,,,FDA-CTU,,56,YR,,F,N,,,20161108,N,OT,US,US,SUSTIVA,"Accident at work;Anxiety;Arthralgia;Hallucination, auditory;Limb injury;Platelet count decreased;Sciatica",,,129237731,HP,,,,,,,129237731,1,HIV infection
12926688,129266882,2,F,20161025,20161104,20161108,20161117,EXP,,UG-GILEAD-2016-0241990,GILEAD,,41,YR,A,M,Y,51.8,KG,20161117,,MD,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Alcohol poisoning,129266882,OT,,,129266882,1,20160619,20161025,,,129266882,1,HIV infection
12927432,129274322,2,F,20160922,20161110,20161109,20161116,EXP,ES-AGEMED-326706347,ES-GILEAD-2016-0242095,GILEAD,,47,YR,A,F,Y,,,20161116,,MD,ES,ES,EFAVIRENZ,Rib fracture,129274322,OT,,,129274322,1,2003,,,,129274322,1,HIV infection
12927583,129275831,1,I,,20161027,20161109,20161109,EXP,,RO-MYLANLABS-2016M1047680,MYLAN,"NEGUT AC, STREINU-CERCEL O, LAZER M, STREINU-CERCEL A. LONG SURVIVOR FAMILY WITH HIV INFECTION. CASE PRESENTATION. BMC-INFECT-DIS 2013;13 (SUPPL. 1): ABSTR. P56.",,,,,Y,,,20161109,,OT,RO,RO,EFAVIRENZ,Blood cholesterol increased;Blood triglycerides increased;Irritability;Lipodystrophy acquired;Sleep disorder,129275831,OT,,,,,,,,,129275831,1,Antiretroviral therapy
12928117,129281171,1,I,,20161027,20161110,20161110,EXP,,GB-CIPLA LTD.-2016GB20864,CIPLA,,,,,,Y,,,20161110,,OT,GB,GB,Efavirenz,Acute hepatic failure;Hepatic encephalopathy;Hyperlipidaemia;Myopathy;Rash;Renal impairment;Transplant dysfunction;Transplant rejection;Viral load increased,129281171,HO,,,,,,,,,129281171,1,HIV infection
12928286,129282861,1,I,,20161028,20161110,20161110,EXP,,GH-CIPLA LTD.-2016GH20824,CIPLA,,,,,,Y,,,20161110,,OT,US,GH,Efavirenz,Disease progression,129282861,OT,,,,,,,,,129282861,1,HIV infection
12928300,129283001,1,I,,20161028,20161110,20161110,EXP,,GH-CIPLA LTD.-2016GH20815,CIPLA,,,,,,Y,,,20161110,,OT,US,GH,Efavirenz,Mental disorder,129283001,OT,,,,,,,,,129283001,1,HIV infection
12928302,129283021,1,I,,20161028,20161110,20161110,EXP,,GH-CIPLA LTD.-2016GH20813,CIPLA,,,,,,Y,,,20161110,,OT,US,GH,Efavirenz,Mental disorder,129283021,OT,,,,,,,,,129283021,1,HIV infection
12928320,129283201,1,I,,20161028,20161110,20161110,EXP,,GH-CIPLA LTD.-2016GH20822,CIPLA,,,,,,Y,,,20161110,,OT,US,GH,Efavirenz,Disease progression,129283201,OT,,,,,,,,,129283201,1,HIV infection
12928336,129283361,1,I,,20161028,20161110,20161110,EXP,,JP-CIPLA LTD.-2016JP20789,CIPLA,"GATANAGA H, HAYASHIDA T, TSUCHIYA K, YOSHINO M, KUWAHARA T, TSUKADA H, ET AL;. SUCCESSFUL EFAVIRENZ DOSE REDUCTION IN HIV TYPE 1-INFECTED INDIVIDUALS WITH CYTOCHROME P450 2B6 *6 AND *26. CLINICAL INFECTIOUS DISEASES. 2007;45:1230 TO 1237",,,,,Y,,,20161110,,OT,JP,JP,Efavirenz,Drug level increased,129283361,OT,,,,,,,,,129283361,1,HIV infection
12928339,129283391,1,I,,20161028,20161110,20161110,EXP,,JP-CIPLA LTD.-2016JP20786,CIPLA,"GATANAGA H, HAYASHIDA T, TSUCHIYA K, YOSHINO M, KUWAHARA T, TSUKADA H ET AL.,. SUCCESSFUL EFAVIRENZ DOSE REDUCTION IN HIV TYPE 1-INFECTED INDIVIDUALS WITH CYTOCHROME P450 2B6 *6 AND *26.. CLINICAL INFECTIOUS DISEASES. 2007;45:1230 TO 1237",,,,,Y,,,20161110,,OT,JP,JP,Efavirenz,Thrombocytopenia,129283391,OT,,,,,,,,,129283391,1,HIV infection
12928353,129283531,1,I,,20161028,20161110,20161110,EXP,,JP-CIPLA LTD.-2016JP20783,CIPLA,"GATANAGA H, HAYASHIDA T, TSUCHIYA K, YOSHINO M, KUWAHARA T, TSUKADA H ET AL.,. SUCCESSFUL EFAVIRENZ DOSE REDUCTION IN HIV TYPE 1 INFECTED INDIVIDUALS WITH CYTOCHROME P450 2B6 *6. CLINICAL INFECTIOUS DISEASES. 2007;45:1230 TO 1237",,,,,Y,,,20161110,,OT,JP,JP,Efavirenz,Dizziness;Drug level increased,129283531,OT,,,,,,,,,129283531,1,HIV infection
12928357,129283571,1,I,,20161028,20161110,20161110,EXP,,GH-CIPLA LTD.-2016GH20826,CIPLA,,,,,,Y,,,20161110,,OT,US,GH,Efavirenz,Disease progression,129283571,OT,,,,,,,,,129283571,1,HIV infection
12928370,129283701,1,I,,20161028,20161110,20161110,EXP,,GH-CIPLA LTD.-2016GH20825,CIPLA,,,,,,Y,,,20161110,,OT,US,GH,Efavirenz,Disease progression,129283701,OT,,,,,,,,,129283701,1,HIV infection
12928388,129283881,1,I,,20161028,20161110,20161110,EXP,,TZ-CIPLA LTD.-2016TZ20751,CIPLA,,,,,,Y,,,20161110,,OT,SE,TZ,Efavirenz,Death,129283881,DE,,,,,,,,,129283881,1,HIV infection
12928396,129283961,1,I,,20161028,20161110,20161110,EXP,,JP-CIPLA LTD.-2016JP20795,CIPLA,"GATANAGA H, HAYASHIDA T, TSUCHIYA K, YOSHINO M, KUWAHARA T, TSUKADA H, ET AL;. SUCCESSFUL EFAVIRENZ DOSE REDUCTION IN HIV TYPE 1-INFECTED INDIVIDUALS WITH CYTOCHROME P450 2B6 *6 AND *26. CLINICAL INFECTIOUS DISEASES. 2007;45:1230 TO 1237",,,,,Y,,,20161110,,OT,JP,JP,Efavirenz,Drug level increased,129283961,OT,,,,,,,,,129283961,1,HIV infection
12928401,129284011,1,I,,20161028,20161110,20161110,EXP,,JP-CIPLA LTD.-2016JP20790,CIPLA,"GATANAGA H, HAYASHIDA T, TSUCHIYA K, YOSHINO M, KUWAHARA T, TSUKADA H, ET AL;. SUCCESSFUL EFAVIRENZ DOSE REDUCTION IN HIV TYPE 1-INFECTED INDIVIDUALS WITH CYTOCHROME P450 2B6 *6 AND *26. CLINICAL INFECTIOUS DISEASES. 2007;45:1230 TO 1237",,,,,Y,,,20161110,,OT,JP,JP,Efavirenz,Drug level increased,129284011,OT,,,,,,,,,129284011,1,HIV infection
12928402,129284021,1,I,,20161028,20161110,20161110,EXP,,JP-CIPLA LTD.-2016JP20794,CIPLA,"GATANAGA H, HAYASHIDA T, TSUCHIYA K, YOSHINO M, KUWAHARA T, TSUKADA H, ET AL;. SUCCESSFUL EFAVIRENZ DOSE REDUCTION IN HIV TYPE 1-INFECTED INDIVIDUALS WITH CYTOCHROME P450 2B6 *6 AND *26. CLINICAL INFECTIOUS DISEASES. 2007;45:1230 TO 1237",,,,,Y,,,20161110,,OT,JP,JP,Efavirenz,Drug level increased,129284021,OT,,,,,,,,,129284021,1,HIV infection
12928475,129284751,1,I,,20161028,20161110,20161110,EXP,,TZ-CIPLA LTD.-2016TZ20754,CIPLA,,,,,,Y,,,20161110,,OT,SE,TZ,Efavirenz,Death,129284751,DE,,,,,,,,,129284751,1,HIV infection
12928479,129284791,1,I,,20161028,20161110,20161110,EXP,,TZ-CIPLA LTD.-2016TZ20753,CIPLA,,,,,,Y,,,20161110,,OT,SE,TZ,Efavirenz,Death,129284791,DE,,,,,,,,,129284791,1,HIV infection
12928519,129285191,1,I,,20161028,20161110,20161110,EXP,,ZW-CIPLA LTD.-2016ZW21029,CIPLA,"DHORO M, ZVADA S, NGARA B, NHACHI C, KADZIRANGE G, CHONZI P ET AL.,. CYP2B6*6, CYP2B6*18, BODY WEIGHT AND SEX ARE PREDICTORS OF EFAVIRENZ PHARMACOKINETICS AND TREATMENT RESPONSE: POPULATION PHARMACOKINETIC MODELING IN AN HIV/AIDS AND TB COHORT IN ZIMBABWE. BMC PHARMACOLOGY AND TOXICOLOGY. 2015;16 (4):1 TO 10",,,,,Y,,,20161110,,OT,ZW,ZW,Efavirenz,Neurotoxicity,129285191,OT,,,,,,,,,129285191,1,Antiretroviral therapy
12928529,129285291,1,I,,20161028,20161110,20161110,EXP,,TZ-CIPLA LTD.-2016TZ20756,CIPLA,,,,,,Y,,,20161110,,OT,SE,TZ,Efavirenz,Death,129285291,DE,,,,,,,,,129285291,1,HIV infection
12928538,129285381,1,I,,20161028,20161110,20161110,EXP,,ZW-CIPLA LTD.-2016ZW20766,CIPLA,"DHORO M, ZVADA S, NGARA B, NHACHI C, KADZIRANGE G, CHONZI P ET AL.,. CYP2B6*6, CYP2B6*18, BODY WEIGHT AND SEX ARE PREDICTORS OF EFAVIRENZ PHARMACOKINETICS AND TREATMENT RESPONSE: POPULATION PHARMACOKINETIC MODELING IN AN HIV/AIDS AND TB COHORT IN ZIMBABWE. BMC PHARMACOLOGY AND TOXICOLOGY. 2015;16 (4):1 TO 10",,,,,Y,,,20161110,,OT,ZW,ZW,Efavirenz,Neurotoxicity,129285381,OT,,,,,,,,,129285381,1,Antiretroviral therapy
12928544,129285441,1,I,,20161028,20161110,20161110,EXP,,ZW-CIPLA LTD.-2016ZW21030,CIPLA,"DHORO M, ZVADA S, NGARA B, NHACHI C, KADZIRANGE G, CHONZI P ET AL.,. CYP2B6*6, CYP2B6*18, BODY WEIGHT AND SEX ARE PREDICTORS OF EFAVIRENZ PHARMACOKINETICS AND TREATMENT RESPONSE: POPULATION PHARMACOKINETIC MODELING IN AN HIV/AIDS AND TB COHORT IN ZIMBABWE. BMC PHARMACOLOGY AND TOXICOLOGY. 2015;16 (4):1 TO 10",,,,,Y,,,20161110,,OT,ZW,ZW,Efavirenz,Neurotoxicity,129285441,OT,,,,,,,,,129285441,1,Antiretroviral therapy
12928555,129285551,1,I,,20161028,20161110,20161110,EXP,,ZW-CIPLA LTD.-2016ZW21031,CIPLA,"DHORO M, ZVADA S, NGARA B, NHACHI C, KADZIRANGE G, CHONZI P ET AL.,. CYP2B6*6, CYP2B6*18, BODY WEIGHT AND SEX ARE PREDICTORS OF EFAVIRENZ PHARMACOKINETICS AND TREATMENT RESPONSE: POPULATION PHARMACOKINETIC MODELING IN AN HIV/AIDS AND TB COHORT IN ZIMBABWE. BMC PHARMACOLOGY AND TOXICOLOGY. 2015;16 (4):1 TO 10",,,,,Y,,,20161110,,OT,ZW,ZW,Efavirenz,Neurotoxicity,129285551,OT,,,,,,,,,129285551,1,Antiretroviral therapy
12928575,129285751,1,I,,20161028,20161110,20161110,EXP,,ZW-CIPLA LTD.-2016ZW21032,CIPLA,"DHORO M, ZVADA S, NGARA B, NHACHI C, KADZIRANGE G, CHONZI P ET AL.,. CYP2B6*6, CYP2B6*18, BODY WEIGHT AND SEX ARE PREDICTORS OF EFAVIRENZ PHARMACOKINETICS AND TREATMENT RESPONSE: POPULATION PHARMACOKINETIC MODELING IN AN HIV/AIDS AND TB COHORT IN ZIMBABWE. BMC PHARMACOLOGY AND TOXICOLOGY. 2015;16 (4):1 TO 10",,,,,Y,,,20161110,,OT,ZW,ZW,Efavirenz,Neurotoxicity,129285751,OT,,,,,,,,,129285751,1,Antiretroviral therapy
12928600,129286001,1,I,,20161028,20161110,20161110,EXP,,ZW-CIPLA LTD.-2016ZW21034,CIPLA,"DHORO M, ZVADA S, NGARA B, NHACHI C, KADZIRANGE G, CHONZI P ET AL.,. CYP2B6*6, CYP2B6*18, BODY WEIGHT AND SEX ARE PREDICTORS OF EFAVIRENZ PHARMACOKINETICS AND TREATMENT RESPONSE: POPULATION PHARMACOKINETIC MODELING IN AN HIV/AIDS AND TB COHORT IN ZIMBABWE. BMC PHARMACOLOGY AND TOXICOLOGY. 2015;16 (4):1 TO 10",,,,,Y,,,20161110,,OT,ZW,ZW,Efavirenz,Neurotoxicity,129286001,OT,,,,,,,,,129286001,1,Antiretroviral therapy
12928603,129286031,1,I,,20161028,20161110,20161110,EXP,,ZW-CIPLA LTD.-2016ZW21033,CIPLA,"DHORO M, ZVADA S, NGARA B, NHACHI C, KADZIRANGE G, CHONZI P ET AL.,. CYP2B6*6, CYP2B6*18, BODY WEIGHT AND SEX ARE PREDICTORS OF EFAVIRENZ PHARMACOKINETICS AND TREATMENT RESPONSE: POPULATION PHARMACOKINETIC MODELING IN AN HIV/AIDS AND TB COHORT IN ZIMBABWE. BMC PHARMACOLOGY AND TOXICOLOGY. 2015;16 (4):1 TO 10",,,,,Y,,,20161110,,OT,ZW,ZW,Efavirenz,Neurotoxicity,129286031,OT,,,,,,,,,129286031,1,Antiretroviral therapy
12928618,129286181,1,I,,20161028,20161110,20161110,EXP,,ZW-CIPLA LTD.-2016ZW21035,CIPLA,"DHORO M, ZVADA S, NGARA B, NHACHI C, KADZIRANGE G, CHONZI P ET AL.,. CYP2B6*6, CYP2B6*18, BODY WEIGHT AND SEX ARE PREDICTORS OF EFAVIRENZ PHARMACOKINETICS AND TREATMENT RESPONSE: POPULATION PHARMACOKINETIC MODELING IN AN HIV/AIDS AND TB COHORT IN ZIMBABWE. BMC PHARMACOLOGY AND TOXICOLOGY. 2015;16 (4):1 TO 10",,,,,Y,,,20161110,,OT,ZW,ZW,Efavirenz,Neurotoxicity,129286181,OT,,,,,,,,,129286181,1,Antiretroviral therapy
12928638,129286381,1,I,20160801,20160803,20161110,20161110,EXP,,UG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-066293,BRISTOL MYERS SQUIBB,,36,YR,,M,Y,56,KG,20161110,,OT,UG,UG,"EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE",Encephalitis;Pulmonary embolism,129286381,LT,,,129286381,1,20151021,20160323,,,129286381,1,Acquired immunodeficiency syndrome
12930223,129302231,1,I,20160630,20161104,20161110,20161110,EXP,,CH-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-095298,BRISTOL MYERS SQUIBB,,42,YR,,M,Y,104,KG,20161110,,OT,CH,CH,EFAVIRENZ,Appendicitis,129302231,HO,,,129302231,2,20151222,,,,129302231,1,HIV infection
12930507,129305074,4,F,20161027,20161203,20161110,20161213,EXP,,MW-GILEAD-2016-0242202,GILEAD,,41,YR,A,M,Y,75.8,KG,20161213,,MD,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia,129305074,HO,,,129305074,1,20150325,20150806,,,129305074,1,Acquired immunodeficiency syndrome
12931537,129315372,2,F,20160421,20161107,20161110,20161115,EXP,,UG-GILEAD-2016-0212079,GILEAD,,36,YR,A,M,Y,66,KG,20161115,,OT,UG,UG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Encephalitis;Neutropenia,129315372,OT,,,129315372,1,20151021,20160801,,,129315372,1,Acquired immunodeficiency syndrome
12931785,129317851,1,I,,20161031,20161111,20161111,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-095784,BRISTOL MYERS SQUIBB,,37,YR,,M,Y,,,20161111,,OT,US,US,EFAVIRENZ,Blood HIV RNA increased;Viraemia,129317851,OT,,,,,,,,,129317851,1,Antiretroviral therapy
12931799,129317991,1,I,,20161031,20161111,20161111,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-095756,BRISTOL MYERS SQUIBB,,23,YR,,M,Y,,,20161111,,OT,US,US,EFAVIRENZ,Blood HIV RNA increased;Viral mutation identified,129317991,OT,,,,,,,,,129317991,1,Antiretroviral therapy
12931923,129319231,1,I,,20161028,20161111,20161111,EXP,,TH-CIPLA LTD.-2016TH20848,CIPLA,,,,,,Y,,,20161111,,OT,US,TH,Efavirenz,Delusion,129319231,OT,,,,,,,,,129319231,1,HIV infection
12931953,129319531,1,I,2005,20161028,20161111,20161111,EXP,,GB-CIPLA LTD.-2016GB20742,CIPLA,,,,,,Y,,,20161111,,OT,US,GB,Tenofovir/Emtricitabine/Efavirenz,Drug level increased;Drug-induced liver injury;Encephalopathy;Lipodystrophy acquired;Pneumonia,129319531,HO,,,129319531,1,201001,,,,129319531,1,HIV infection
12934627,129346273,3,F,2007,20161213,20161111,20161216,EXP,,GB-GILEAD-2016-0242737,GILEAD,,71,YR,E,M,Y,67,KG,20161216,,MD,GB,GB,EFAVIRENZ,Bone disorder;Glomerular filtration rate decreased;Osteopenia;Renal impairment,129346273,OT,,,129346273,1,2002,2009,,,129346273,1,Product used for unknown indication
12939090,129390902,2,F,,20161108,20161115,20161121,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-092540,BRISTOL MYERS SQUIBB,,51,YR,,M,Y,,,20161121,,CN,GB,GB,SUSTIVA,Activities of daily living impaired;Diarrhoea;Malaise;Product substitution issue,129390902,DS,,,,,,,,,129390902,1,Product used for unknown indication
12939475,129394751,1,I,,20161102,20161115,20161115,EXP,,ES-CIPLA LTD.-2016ES21009,CIPLA,"GANTNER P, BANI-SADR F, GARRAFFO R, ROGER PM, TREGER M, JOVELIN T ET AL.,. SWITCH TO RITONAVIR-BOOSTED VERSUS UNBOOSTED ATAZANAVIR PLUS RALTEGRAVIR DUAL-DRUG THERAPY LEADS TO SIMILAR EFFICACY AND SAFETY OUTCOMES IN CLINICAL PRACTICE. PLOS ONE. 2016;1 TO 13",,,,,Y,,,20161115,,OT,FR,ES,Efavirenz,Diabetes mellitus;Diarrhoea;Drug resistance;Dyslipidaemia;Lipodystrophy acquired;Osteoporosis;Virologic failure,129394751,OT,,,,,,,,,129394751,1,HIV infection
12942708,129427081,1,I,,20161104,20161114,20161114,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-094642,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20161114,,CN,US,US,SUSTIVA,Depression;Drug abuse;Hallucination;Insomnia;Mood swings;Suicidal ideation,129427081,OT,,,129427081,1,2002,,,,129427081,1,HIV infection
12945570,129455702,2,F,20160906,20161107,20161116,20161121,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-096060,BRISTOL MYERS SQUIBB,,35,YR,,F,Y,,,20161121,,CN,CN,CN,EFAVIRENZ,Drug eruption,129455702,HO,,,129455702,1,20160902,20160906,,,129455702,1,HIV infection
12945922,129459221,1,I,20160822,20161107,20161116,20161116,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-096064,BRISTOL MYERS SQUIBB,,61,YR,,M,Y,50,KG,20161116,,CN,CN,CN,EFAVIRENZ,Liver injury,129459221,OT,,,129459221,1,20160226,20160822,,,129459221,1,Viral infection
12946469,129464691,1,I,,20161104,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21146,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116,,OT,NL,GH,Efavirenz,Hearing disability;Vestibular disorder,129464691,OT,,,,,,,,,129464691,1,HIV infection
12946470,129464701,1,I,,20161104,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21141,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116,,OT,NL,GH,Efavirenz,Cardiovascular disorder,129464701,OT,,,,,,,,,129464701,1,HIV infection
12946475,129464751,1,I,,20161104,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21145,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL;. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116,,OT,NL,GH,Efavirenz,Nervous system disorder,129464751,OT,,,,,,,,,129464751,1,HIV infection
12946488,129464881,1,I,,20161104,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21140,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116,,OT,NL,GH,Efavirenz,Gastrointestinal disorder,129464881,OT,,,,,,,,,129464881,1,HIV infection
12946494,129464941,1,I,,20161104,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21143,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116,,OT,NL,GH,Efavirenz,Mental disorder,129464941,OT,,,,,,,,,129464941,1,HIV infection
12946497,129464971,1,I,,20161104,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21142,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116,,OT,NL,GH,Efavirenz,Cardiovascular disorder,129464971,OT,,,,,,,,,129464971,1,HIV infection
12946521,129465211,1,I,,20161104,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21150,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116,,OT,NL,GH,Efavirenz,Cardiovascular disorder,129465211,OT,,,,,,,,,129465211,1,HIV infection
12946522,129465221,1,I,,20161104,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21156,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116,,OT,NL,GH,Efavirenz,Musculoskeletal disorder,129465221,OT,,,,,,,,,129465221,1,HIV infection
12946541,129465411,1,I,,20161104,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21153,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116,,OT,NL,GH,Efavirenz,Cardiovascular disorder,129465411,OT,,,,,,,,,129465411,1,HIV infection
12946566,129465661,1,I,,20161104,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21171,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116,,OT,NL,GH,Efavirenz,Mental disorder,129465661,OT,,,,,,,,,129465661,1,HIV infection
12946584,129465841,1,I,,20161104,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21147,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116,,OT,NL,GH,Efavirenz,Gastrointestinal disorder,129465841,OT,,,,,,,,,129465841,1,HIV infection
12946590,129465901,1,I,,20161104,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21158,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116,,OT,NL,GH,Efavirenz,Musculoskeletal disorder,129465901,OT,,,,,,,,,129465901,1,HIV infection
12946610,129466101,1,I,,20161104,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21173,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116,,OT,NL,GH,Efavirenz,Gastrointestinal disorder,129466101,OT,,,,,,,,,129466101,1,HIV infection
12946612,129466121,1,I,,20161104,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21179,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116,,OT,NL,GH,Efavirenz,Malnutrition;Metabolic disorder,129466121,OT,,,,,,,,,129466121,1,HIV infection
12946619,129466191,1,I,,20161104,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21178,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116,,OT,NL,GH,Efavirenz,Malnutrition;Metabolic disorder,129466191,OT,,,,,,,,,129466191,1,HIV infection
12946635,129466351,1,I,,20161104,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21181,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116,,OT,NL,GH,Efavirenz,Neuropathy peripheral,129466351,OT,,,,,,,,,129466351,1,HIV infection
12946637,129466371,1,I,,20161104,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21182,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116,,OT,NL,GH,Efavirenz,Neuropathy peripheral,129466371,OT,,,,,,,,,129466371,1,HIV infection
12946650,129466501,1,I,,20161104,20161116,20161116,EXP,,NL-CIPLA LTD.-2016GH21186,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL;. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161116,,OT,NL,GH,Efavirenz,Neuropathy peripheral,129466501,OT,,,,,,,,,129466501,1,HIV infection
12947636,129476362,2,F,,20161027,20161116,20161205,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-092524,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20161205,,PH,US,US,SUSTIVA,Cyst removal;Dysphagia;Gastrointestinal tube insertion;Tonsillar cyst,129476362,OT,,,,,,,,,129476362,1,HIV infection
12948028,129480281,1,I,20160630,20161109,20161116,20161116,EXP,,CH-GILEAD-2016-0242742,GILEAD,,42,YR,A,M,Y,104,KG,20161116,,OT,CH,CH,EFAVIRENZ,Appendicitis,129480281,HO,,,129480281,1,20160608,20160607,,,129480281,1,HIV infection
12948678,129486781,1,I,,20161104,20161117,20161117,EXP,,GH-CIPLA LTD.-2016GH21133,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL;. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117,,OT,GH,GH,Efavirenz,Mental disorder,129486781,OT,,,,,,,,,129486781,1,HIV infection
12948679,129486791,1,I,,20161104,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21139,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117,,OT,NL,GH,Efavirenz,Gastrointestinal disorder,129486791,OT,,,,,,,,,129486791,1,HIV infection
12948680,129486801,1,I,,20161104,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21138,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117,,OT,NL,GH,Efavirenz,Gastrointestinal disorder,129486801,OT,,,,,,,,,129486801,1,HIV infection
12948681,129486811,1,I,,20161104,20161117,20161117,EXP,,GH-CIPLA LTD.-2016GH21135,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL;. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117,,OT,GH,GH,Efavirenz,Nervous system disorder;Neuropathy peripheral,129486811,OT,,,,,,,,,129486811,1,HIV infection
12948682,129486821,1,I,,20161104,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21136,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117,,OT,NL,GH,Efavirenz,Gastrointestinal disorder,129486821,OT,,,,,,,,,129486821,1,HIV infection
12948683,129486831,1,I,,20161104,20161117,20161117,EXP,,GH-CIPLA LTD.-2016GH21134,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL;. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117,,OT,GH,GH,Efavirenz,Mental disorder,129486831,OT,,,,,,,,,129486831,1,HIV infection
12948684,129486841,1,I,,20161104,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21131,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117,,OT,NL,GH,Efavirenz,Mental disorder,129486841,OT,,,,,,,,,129486841,1,HIV infection
12948686,129486861,1,I,,20161104,20161117,20161117,EXP,,GH-CIPLA LTD.-2016GH21132,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL;. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117,,OT,GH,GH,Efavirenz,Mental disorder,129486861,OT,,,,,,,,,129486861,1,HIV infection
12948705,129487051,1,I,,20161104,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21144,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117,,OT,NL,GH,Efavirenz,Musculoskeletal disorder,129487051,OT,,,,,,,,,129487051,1,HIV infection
12948728,129487281,1,I,,20161104,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21151,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117,,OT,NL,GH,Efavirenz,Mental disorder,129487281,OT,,,,,,,,,129487281,1,HIV infection
12948730,129487301,1,I,,20161104,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21160,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117,,OT,NL,GH,Efavirenz,Hepatobiliary disease,129487301,OT,,,,,,,,,129487301,1,HIV infection
12948742,129487421,1,I,,20161104,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21149,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117,,OT,NL,GH,Efavirenz,Red blood cell abnormality,129487421,OT,,,,,,,,,129487421,1,HIV infection
12948801,129488011,1,I,,20161104,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21164,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117,,OT,NL,GH,Efavirenz,Malnutrition;Metabolic disorder,129488011,OT,,,,,,,,,129488011,1,HIV infection
12948857,129488571,1,I,,20161104,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21168,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117,,OT,NL,GH,Efavirenz,Mental disorder,129488571,OT,,,,,,,,,129488571,1,HIV infection
12948875,129488751,1,I,,20161104,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21176,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117,,OT,NL,GH,Efavirenz,Malnutrition;Metabolic disorder,129488751,OT,,,,,,,,,129488751,1,HIV infection
12948890,129488901,1,I,,20161104,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21175,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117,,OT,NL,GH,Efavirenz,Gastrointestinal disorder,129488901,OT,,,,,,,,,129488901,1,HIV infection
12948930,129489301,1,I,,20161104,20161117,20161117,EXP,,NL-CIPLA LTD.-2016GH21174,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161117,,OT,NL,GH,Efavirenz,Malnutrition;Metabolic disorder,129489301,OT,,,,,,,,,129489301,1,HIV infection
12951155,129511551,1,I,,20161109,20161117,20161117,EXP,,TH-GILEAD-2016-0243160,GILEAD,"V. ORANRAP, S. TREEPRASERTSUK. AUTOIMMUNE HEPATITIS (AIH) TRIGGERS BY POPPER IN A HIV-INFECTED PATIENT AND CASE SERIES OF AIH-HIV IN THAILAND. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2016;111 (1):1851-1852",42,YR,A,F,Y,,,20161117,,OT,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Autoimmune hepatitis,129511551,OT,,,,,,,,,129511551,1,HIV infection
12951234,129512341,1,I,,20161109,20161117,20161117,EXP,,TH-GILEAD-2016-0243158,GILEAD,"V. ORANRAP, S. TREEPRASERTSUK. AUTOIMMUNE HEPATITIS (AIH) TRIGGERS BY POPPER IN A HIV-INFECTED PATIENT AND CASE SERIES OF AIH-HIV IN THAILAND. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2016;111 (1):1851-1852",46,YR,A,F,Y,,,20161117,,OT,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Autoimmune hepatitis,129512341,OT,,,,,,,,,129512341,1,HIV infection
12951900,129519001,1,I,,20161109,20161117,20161117,EXP,,TH-GILEAD-2016-0243162,GILEAD,"V. ORANRAP, S. TREEPRASERTSUK. AUTOIMMUNE HEPATITIS (AIH) TRIGGERS BY POPPER IN A HIV-INFECTED PATIENT AND CASE SERIES OF AIH-HIV IN THAILAND. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2016;111 (1):1851-1852",52,YR,A,F,Y,,,20161117,,OT,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Autoimmune hepatitis,129519001,OT,,,,,,,,,129519001,1,HIV infection
12952198,129521981,1,I,,20161109,20161117,20161117,EXP,,TH-GILEAD-2016-0243159,GILEAD,"V. ORANRAP, S. TREEPRASERTSUK. AUTOIMMUNE HEPATITIS (AIH) TRIGGERS BY POPPER IN A HIV-INFECTED PATIENT AND CASE SERIES OF AIH-HIV IN THAILAND. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2016;111 (1):1851-1852",53,YR,A,F,Y,,,20161117,,OT,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Autoimmune hepatitis,129521981,OT,,,,,,,,,129521981,1,HIV infection
12952355,129523551,1,I,,20161109,20161117,20161117,EXP,,TH-GILEAD-2016-0243161,GILEAD,"V. ORANRAP, S. TREEPRASERTSUK. AUTOIMMUNE HEPATITIS (AIH) TRIGGERS BY POPPER IN A HIV-INFECTED PATIENT AND CASE SERIES OF AIH-HIV IN THAILAND. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2016;111 (1):1851-1852",48,YR,A,F,Y,,,20161117,,OT,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Autoimmune hepatitis,129523551,OT,,,,,,,,,129523551,1,HIV infection
12952797,129527971,1,I,,20161109,20161117,20161117,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-096318,BRISTOL MYERS SQUIBB,,,,,F,Y,85,KG,20161117,,MD,US,US,EFAVIRENZ,Diarrhoea;Headache;Nausea;Pruritus;Swelling;Vomiting,,,,,129527971,1,20160829,,,,129527971,1,Hepatitis C
12953088,129530881,1,I,,20161109,20161117,20161117,EXP,,TH-GILEAD-2016-0243152,GILEAD,"V. ORANRAP, S. TREEPRESERTSUK,. AUTOIMMUNE HEPATITIS (AIH) TRIGGERS BY POPPER IN A HIV-INFECTED PATIENT AND CASE SERIES OF AIH-HIV IN THAILAND. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2016;111 (1):1851-1852",47,YR,A,M,Y,,,20161117,,OT,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Autoimmune hepatitis,129530881,OT,,,,,,,,,129530881,1,HIV infection
12953112,129531121,1,I,,20161109,20161117,20161117,EXP,,TH-GILEAD-2016-0243154,GILEAD,"V. ORANRAP, S. TREEPRASERTSUK. AUTOIMMUNE HEPATITIS (AIH) TRIGGERS BY POPPER IN A HIV-INFECTED PATIENT AND CASE SERIES OF AIH-HIV IN THAILAND. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2016;111 (1):1851-1852",58,YR,A,M,Y,,,20161117,,OT,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Autoimmune hepatitis,129531121,OT,,,,,,,,,129531121,1,HIV infection
12953128,129531281,1,I,,20161109,20161117,20161117,EXP,,TH-GILEAD-2016-0243155,GILEAD,"V. ORANRAP, S. TREEPRASURTSUK. AUTOIMMUNE HEPATITIS (AIH) TRIGGERS BY POPPER IN A HIV-INFECTED PATIENT AND CASE SERIES OF AIH-HIV IN THAILAND. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2016;111 (1):1851-1852",27,YR,A,M,Y,,,20161117,,OT,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Autoimmune hepatitis,129531281,OT,,,,,,,,,129531281,1,HIV infection
12953129,129531291,1,I,,20161109,20161117,20161117,EXP,,TH-GILEAD-2016-0243156,GILEAD,"V. ORANRAP, S. TREEPRASERTSUK. AUTOIMMUNE HEPATITIS (AIH) TRIGGERS BY POPPER IN A HIV-INFECTED PATIENT AND CASE SERIES OF AIH-HIV IN THAILAND. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2016;111 (1):1851-1852",44,YR,A,F,Y,,,20161117,,OT,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Autoimmune hepatitis,129531291,OT,,,,,,,,,129531291,1,HIV infection
12953147,129531471,1,I,,20161109,20161117,20161117,EXP,,TH-GILEAD-2016-0243157,GILEAD,"V. ORANRAP, S. TREEPRASERTSUK. AUTOIMMUNE HEPATITIS (AIH) TRIGGERS BY POPPER IN A HIV-INFECTED PATIENT AND CASE SERIES OF AIH-HIV IN THAILAND. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2016;111 (1):1851-1852",46,YR,A,F,Y,,,20161117,,OT,TH,TH,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Autoimmune hepatitis,129531471,OT,,,,,,,,,129531471,1,HIV infection
12953222,129532222,2,F,20151106,20161130,20161117,20161130,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-096103,BRISTOL MYERS SQUIBB,,38,YR,,F,Y,148.8,KG,20161130,,OT,US,US,EFAVIRENZ,Asthma,129532222,HO,,,129532222,1,20151030,,,,129532222,1,HIV infection
12953344,129533441,1,I,,20161109,20161117,20161117,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-096332,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20161117,,MD,IT,IT,EFAVIRENZ,Cytomegalovirus infection;Hepatocellular carcinoma;Nervous system disorder;Transaminases increased,129533441,OT,,,129533441,1,20081016,,,,129533441,1,HIV infection
12953684,129536843,3,F,20161102,20161207,20161117,20161214,EXP,,MW-GILEAD-2016-0242786,GILEAD,,35,YR,A,M,Y,60,KG,20161214,,OT,MW,MW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anaemia,129536843,HO,,,129536843,1,20150714,20160926,,,129536843,1,Kaposi's sarcoma AIDS related
12953694,129536943,3,F,20161109,20161220,20161117,20161229,EXP,,ZW-GILEAD-2016-0243462,GILEAD,,36,YR,A,M,Y,77.5,KG,20161229,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Kaposi's sarcoma;Sepsis,129536943,OT,,,129536943,1,20150423,20161109,,,129536943,1,Kaposi's sarcoma AIDS related
12953708,129537081,1,I,,20161104,20161118,20161118,EXP,,NL-CIPLA LTD.-2016GH21126,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA, ET.AL,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161118,,OT,NL,GH,Efavirenz,Red blood cell abnormality,129537081,OT,,,,,,,,,129537081,1,HIV infection
12953747,129537471,1,I,,20161104,20161118,20161118,EXP,,NL-CIPLA LTD.-2016GH21129,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA, ET.AL,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161118,,OT,NL,GH,Efavirenz,Red blood cell abnormality,129537471,OT,,,,,,,,,129537471,1,HIV infection
12953755,129537551,1,I,,20161104,20161118,20161118,EXP,,NL-CIPLA LTD.-2016GH21128,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA, ET.AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161118,,OT,NL,GH,Efavirenz,Red blood cell abnormality,129537551,OT,,,,,,,,,129537551,1,HIV infection
12953758,129537581,1,I,,20161104,20161118,20161118,EXP,,NL-CIPLA LTD.-2016GH21127,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HG, YANKEY BA, ET.AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161118,,OT,NL,GH,Efavirenz,Red blood cell abnormality,129537581,OT,,,,,,,,,129537581,1,HIV infection
12953780,129537801,1,I,,20161104,20161118,20161118,EXP,,NL-CIPLA LTD.-2016GH21130,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161118,,OT,NL,GH,Efavirenz,Neuropathy peripheral,129537801,OT,,,,,,,,,129537801,1,HIV infection
12953837,129538371,1,I,,20161104,20161118,20161118,EXP,,NL-CIPLA LTD.-2016GH21193,CIPLA,"TETTEH RA, NARTEY ET, LARTEY M, MANTEL-TEEUWISSE AK, LEUFKENS HGM, YANKEY BA, ET AL.,. ASSOCIATION BETWEEN THE OCCURRENCE OF ADVERSE DRUG EVENTS AND MODIFICATION OF FIRST-LINE HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN GHANAIAN HIV PATIENTS. DRUG SAF. 2016;39:1139 TO 1149",,,,,Y,,,20161118,,OT,NL,GH,Efavirenz,Neuropathy peripheral,129538371,OT,,,,,,,,,129538371,1,HIV infection
12957690,129576901,1,I,,20161107,20161119,20161119,EXP,,RO-HETERO LABS LTD-1059796,HETERO,,,,,F,Y,,,20161119,,,COUNTRY NOT SPECIFIED,RO,Efavirenz,Lipodystrophy acquired;Neuropathy peripheral;Nightmare;Sleep disorder,129576901,OT,,,,,,,,,129576901,1,HIV infection
12962077,129620771,1,I,,20161110,20161121,20161121,EXP,,US-MYLANLABS-2016M1050140,MYLAN,"BUNNELL KL, VIBHAKAR S, GLOWACKI RC, GALLAGHER MA, OSEI AM, HUHN G. NEPHROTOXICITY ASSOCIATED WITH CONCOMITANT USE OF LEDIPASVIR-SOFOSBUVIR AND TENOFOVIR IN A PATIENT WITH HEPATITIS C VIRUS AND HUMAN IMMUNODEFICIENCY VIRUS COINFECTION. PHARMACOTHERAPY 2016;36(9):E148-E153.",,,,,Y,,,20161121,,OT,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Drug interaction;Fall;Medication error,129620771,HO,,,,,,,,,129620771,1,Hypertension
12962495,129624952,2,F,,20161116,20161121,20161123,EXP,,NG-GILEAD-2016-0243617,GILEAD,,40,YR,A,M,Y,72,KG,20161123,,MD,NG,NG,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident;Hypertensive heart disease;Myocardial infarction,129624952,DE,,,129624952,1,20130307,20160718,,,129624952,1,HIV infection
12962925,129629251,1,I,,20161107,20161122,20161122,EXP,,RO-HETERO LABS LTD-1059902,HETERO,ALINA CRISTINA NEGUT. LONG SURVIVOR FAMILY WITH HIV INFECTION. CASE PRESENTATION. BMC-INFECT-DIS 2013;13(SUPPL 1):P56.,,,,M,Y,,,20161122,,OT,RO,RO,Efavirenz,Bladder irritation;Blood cholesterol increased;Blood triglycerides increased;Lipodystrophy acquired;Sleep disorder,129629251,OT,,,,,,,,,129629251,1,HIV infection
12963223,129632232,2,F,20160725,20161116,20161122,20161124,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-099242,BRISTOL MYERS SQUIBB,,32,YR,,F,Y,46,KG,20161124,,MD,FR,FR,EFAVIRENZ,Anaemia,129632232,OT,,,,,,,,,129632232,1,Tuberculosis
12963459,129634591,1,I,,20161110,20161122,20161122,EXP,,TH-CIPLA LTD.-2016TH21437,CIPLA,"MANOSUTHI W, SUKASEM C, THONGYEN S, NILKAMHANG S, MANOSUTHI S, SUNGKANUPARPH S. CARRYING CYP2B6 HAPLOTYPE *1/*1 COINFECTED HIV AND TUBERCULOSIS PATIENTS COMPROMISES EFAVIRENZ CONCENTRATION IN CYP2B6 18492T?C POLYMORPHISM. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58 (4):2268 TO 2273",,,,,Y,,,20161122,,OT,TH,TH,Efavirenz,Drug resistance;Virologic failure,129634591,OT,,,,,,,,,129634591,1,HIV infection
12963601,129636011,1,I,,20161110,20161122,20161122,EXP,,TH-CIPLA LTD.-2016TH21438,CIPLA,"MANOSUTHI W, SUKASEM C, THONGYEN S, NILKAMHANG S, MANOSUTHI S, SUNGKANUPARPH S.. CARRYING CYP2B6 HAPLOTYPE *1/*1 COINFECTED HIV AND TUBERCULOSIS PATIENTS COMPROMISES EFAVIRENZ CONCENTRATION IN CYP2B6 18492T?C POLYMORPHISM. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58 (4):2268 TO 2273",,,,,Y,,,20161122,,OT,TH,TH,Efavirenz,Drug resistance;Virologic failure,129636011,OT,,,,,,,,,129636011,1,HIV infection
12965347,129653471,1,I,2003,20150127,20161122,20161122,PER,,US-GILEAD-2016-0244335,GILEAD,,69,YR,E,M,Y,,,20161122,,CN,US,US,SUSTIVA,Drug interaction,,,,,129653471,1,2003,201412,,,129653471,1,HIV infection
12966008,129660081,1,I,20151106,20161118,20161122,20161122,EXP,,US-GILEAD-2016-0244405,GILEAD,,38,YR,A,F,Y,148.8,KG,20161122,,MD,US,US,EFAVIRENZ,Asthma,129660081,HO,,,129660081,1,20151030,,,,129660081,1,HIV infection
12966250,129662501,1,I,20161116,20161117,20161122,20161122,EXP,,IT-GILEAD-2016-0244288,GILEAD,,61,YR,A,M,Y,,,20161122,,MD,IT,IT,EFAVIRENZ,Pancytopenia,129662501,OT,,,129662501,1,200611,201611,,,129662501,1,HIV infection
12966370,129663701,1,I,,,20161121,20161121,DIR,US-FDA-356251,,FDA-CTU,,50,YR,,M,N,72,KG,20161121,N,CN,US,US,SUSTIVA,Abdominal distension;Asthenia;Hepatic enzyme increased;Hepatic lesion;Internal haemorrhage;Pancreatic disorder;Product formulation issue;Renal disorder,129663701,OT,129663701,CSM,,,,,,,129663701,1,HIV infection
12966901,129669011,1,I,,20161110,20161123,20161123,EXP,,TH-CIPLA LTD.-2016TH21439,CIPLA,"MANOSUTHI W, SUKASEM C, THONGYEN S, NILKAMHANG S, MANOSUTHI S, SUNGKANUPARPH S. CARRYING CYP2B6 HAPLOTYPE *1/*1 COINFECTED HIV AND TUBERCULOSIS PATIENTS COMPROMISES EFAVIRENZ CONCENTRATION IN CYP2B6 18492T?C POLYMORPHISM. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58 (4):2268 TO 2273",,,,,Y,,,20161123,,OT,TH,TH,Efavirenz,Drug resistance;Virologic failure,129669011,OT,,,,,,,,,129669011,1,HIV infection
12966918,129669181,1,I,,20161110,20161123,20161123,EXP,,TH-CIPLA LTD.-2016TH21441,CIPLA,"MANOSUTHI W, SUKASEM C, THONGYEN S, NILKAMHANG S, MANOSUTHI S, SUNGKANUPARPH S. CARRYING CYP2B6 HAPLOTYPE *1/*1 COINFECTED HIV AND TUBERCULOSIS PATIENTS COMPROMISES EFAVIRENZ CONCENTRATION IN CYP2B6 18492T?C POLYMORPHISM. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58 (4):2268 TO 2273",,,,,Y,,,20161123,,OT,TH,TH,Efavirenz,Drug resistance;Virologic failure,129669181,OT,,,,,,,,,129669181,1,HIV infection
12966922,129669221,1,I,,20161110,20161123,20161123,EXP,,TH-CIPLA LTD.-2016TH21440,CIPLA,"MANOSUTHI W, SUKASEM C, THONGYEN S, NILKAMHANG S, MANOSUTHI S, SUNGKANUPARPH S. CARRYING CYP2B6 HAPLOTYPE *1/*1 COINFECTED HIV AND TUBERCULOSIS PATIENTS COMPROMISES EFAVIRENZ CONCENTRATION IN CYP2B6 18492T?C POLYMORPHISM. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58 (4):2268 TO 2273",,,,,Y,,,20161123,,OT,TH,TH,Efavirenz,Drug resistance;Virologic failure,129669221,OT,,,,,,,,,129669221,1,HIV infection
12966938,129669381,1,I,,20161110,20161123,20161123,EXP,,TH-CIPLA LTD.-2016TH21443,CIPLA,"MANOSUTHI W, SUKASEM C, THONGYEN S, NILKAMHANG S, MANOSUTHI S, SUNGKANUPARPH S. CARRYING CYP2B6 HAPLOTYPE *1/*1 COINFECTED HIV AND TUBERCULOSIS PATIENTS COMPROMISES EFAVIRENZ CONCENTRATION IN CYP2B6 18492T?C POLYMORPHISM. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58 (4):2268 TO 2273",,,,,Y,,,20161123,,OT,TH,TH,Efavirenz,Drug resistance;Virologic failure,129669381,OT,,,,,,,,,129669381,1,HIV infection
12966944,129669441,1,I,,20161110,20161123,20161123,EXP,,TH-CIPLA LTD.-2016TH21442,CIPLA,"MANOSUTHI W, SUKASEM C, THONGYEN S, NILKAMHANG S, MANOSUTHI S, SUNGKANUPARPH S. CYP2B6 18492T T-}C POLYMORPHISM COMPROMISES EFAVIRENZ CONCENTRATION IN COINFECTED HIV AND TUBERCULOSIS PATIENTS CARRYING CYP2B6 HAPLOTYPE *1/*1. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58(4):2268 TO 2273",,,,,Y,,,20161123,,OT,TH,TH,Efavirenz,Drug resistance;Virologic failure,129669441,OT,,,,,,,,,129669441,1,HIV infection
12966949,129669491,1,I,,20161110,20161123,20161123,EXP,,TH-CIPLA LTD.-2016TH21448,CIPLA,"MANOSUTHI W, SUKASEM C, THONGYEN S, NILKAMHANG S, MANOSUTHI S, SUNGKANUPARPH S. CARRYING CYP2B6 HAPLOTYPE *1/*1 COINFECTED HIV AND TUBERCULOSIS PATIENTS COMPROMISES EFAVIRENZ CONCENTRATION IN CYP2B6 18492T?C POLYMORPHISM. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58 (4):2268 TO 2273",,,,,Y,,,20161123,,OT,TH,TH,Efavirenz,Death,129669491,DE,,,,,,,,,129669491,1,HIV infection
12966975,129669751,1,I,,20161110,20161123,20161123,EXP,,TH-CIPLA LTD.-2016TH21445,CIPLA,"MANOSUTHI W, SUKASEM C, THONGYEN S, NILKAMHANG S, MANOSUTHI S, SUNGKANUPARPH S. CARRYING CYP2B6 HAPLOTYPE *1/*1 COINFECTED HIV AND TUBERCULOSIS PATIENTS COMPROMISES EFAVIRENZ CONCENTRATION IN CYP2B6 18492T?C POLYMORPHISM. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58 (4):2268 TO 2273",,,,,Y,,,20161123,,OT,TH,TH,Efavirenz,Drug resistance;Virologic failure,129669751,OT,,,,,,,,,129669751,1,HIV infection
12966997,129669971,1,I,,20161110,20161123,20161123,EXP,,TH-CIPLA LTD.-2016TH21446,CIPLA,"MANOSUTHI W, SUKASEM C, THONGYEN S, NILKAMHANG S, MANOSUTHI S, SUNGKANUPARPH S. CARRYING CYP2B6 HAPLOTYPE *1/*1 COINFECTED HIV AND TUBERCULOSIS PATIENTS COMPROMISES EFAVIRENZ CONCENTRATION IN CYP2B6 18492T?C POLYMORPHISM. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58 (4):2268 TO 2273",,,,,Y,,,20161123,,OT,TH,TH,Efavirenz,Death,129669971,DE,,,,,,,,,129669971,1,HIV infection
12967000,129670001,1,I,,20161110,20161123,20161123,EXP,,TH-CIPLA LTD.-2016TH21447,CIPLA,"MANOSUTHI W, SUKASEM C, THONGYEN S, NILKAMHANG S, MANOSUTHI S, SUNGKANUPARPH S. CARRYING CYP2B6 HAPLOTYPE *1/*1 COINFECTED HIV AND TUBERCULOSIS PATIENTS COMPROMISES EFAVIRENZ CONCENTRATION IN CYP2B6 18492T?C POLYMORPHISM. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58 (4):2268 TO 2273",,,,,Y,,,20161123,,OT,TH,TH,Efavirenz,Death,129670001,DE,,,,,,,,,129670001,1,HIV infection
12967019,129670191,1,I,,20161110,20161123,20161123,EXP,,ZA-CIPLA LTD.-2016ZA21405,CIPLA,"GOUNDEN V, VAN NIEKERK C, SNYMAN T, GEORGE JA. PRESENCE OF THE CYP2B6 516G-} T POLYMORPHISM, INCREASED PLASMA EFAVIRENZ CONCENTRATIONS AND EARLY NEUROPSYCHIATRIC SIDE EFFECTS IN SOUTH AFRICAN HIV-INFECTED PATIENTS. AIDS RESEARCH AND THERAPY. 2010;7 (32):1 TO 9",,,,,Y,,,20161123,,OT,ZA,ZA,Efavirenz,Virologic failure,129670191,OT,,,,,,,,,129670191,1,HIV infection
12967030,129670301,1,I,,20161110,20161123,20161123,EXP,,ZA-CIPLA LTD.-2016ZA21367,CIPLA,"GOUNDEN V, VAN NIEKERK C, SNYMAN T, GEORGE JA. PRESENCE OF THE CYP2B6 516G} T POLYMORPHISM, INCREASED PLASMA EFAVIRENZ CONCENTRATIONS AND EARLY NEUROPSYCHIATRIC SIDE EFFECTS IN SOUTH AFRICAN HIV-INFECTED PATIENTS. AIDS RESEARCH AND THERAPY. 2010;7 (32):1 TO 9",,,,,Y,,,20161123,,OT,ZA,ZA,Efavirenz,Virologic failure,129670301,OT,,,,,,,,,129670301,1,HIV infection
12967313,129673131,1,I,,20161110,20161123,20161123,EXP,,ZA-CIPLA LTD.-2016ZA21406,CIPLA,"GOUNDEN V, VAN NIEKERK C, SNYMAN T, GEORGE JA. PRESENCE OF THE CYP2B6 516G} T POLYMORPHISM, INCREASED PLASMA EFAVIRENZ CONCENTRATIONS AND EARLY NEUROPSYCHIATRIC SIDE EFFECTS IN SOUTH AFRICAN HIV-INFECTED PATIENTS. AIDS RESEARCH AND THERAPY. 2010;7 (32):1 TO 9",,,,,Y,,,20161123,,OT,ZA,ZA,Efavirenz,Virologic failure,129673131,OT,,,,,,,,,129673131,1,HIV infection
12967328,129673281,1,I,,20161110,20161123,20161123,EXP,,ZA-CIPLA LTD.-2016ZA21407,CIPLA,"GOUNDEN V, VAN NIEKERK C, SNYMAN T, GEORGE JA. PRESENCE OF THE CYP2B6 516G} T POLYMORPHISM, INCREASED PLASMA EFAVIRENZ CONCENTRATIONS AND EARLY NEUROPSYCHIATRIC SIDE EFFECTS IN SOUTH AFRICAN HIV-INFECTED PATIENTS. AIDS RESEARCH AND THERAPY. 2010;7 (32):1 TO 9",,,,,Y,,,20161123,,OT,ZA,ZA,Efavirenz,Virologic failure,129673281,OT,,,,,,,,,129673281,1,HIV infection
12967340,129673401,1,I,,20161110,20161123,20161123,EXP,,ZA-CIPLA LTD.-2016ZA21409,CIPLA,"GOUNDEN V, VAN NIEKERK C, SNYMAN T, GEORGE JA. PRESENCE OF THE CYP2B6 516G} T POLYMORPHISM, INCREASED PLASMA EFAVIRENZ CONCENTRATIONS AND EARLY NEUROPSYCHIATRIC SIDE EFFECTS IN SOUTH AFRICAN HIV-INFECTED PATIENTS. AIDS RESEARCH AND THERAPY. 2010;7 (32):1 TO 9",,,,,Y,,,20161123,,OT,ZA,ZA,Efavirenz,Drug level above therapeutic;Virologic failure,129673401,OT,,,,,,,,,129673401,1,HIV infection
12967345,129673451,1,I,,20161110,20161123,20161123,EXP,,ZA-CIPLA LTD.-2016ZA21408,CIPLA,"GOUNDEN V, VAN NIEKERK C, SNYMAN T, GEORGE JA. PRESENCE OF THE CYP2B6 516G} T POLYMORPHISM, INCREASED PLASMA EFAVIRENZ CONCENTRATIONS AND EARLY NEUROPSYCHIATRIC SIDE EFFECTS IN SOUTH AFRICAN HIV-INFECTED PATIENTS. AIDS RESEARCH AND THERAPY. 2010;7 (32):1 TO 9",,,,,Y,,,20161123,,OT,ZA,ZA,Efavirenz,Drug level below therapeutic;Virologic failure,129673451,OT,,,,,,,,,129673451,1,HIV infection
12967347,129673471,1,I,,20161110,20161123,20161123,EXP,,ZA-CIPLA LTD.-2016ZA21410,CIPLA,"GOUNDEN V, VAN NIEKERK C, SNYMAN T, GEORGE JA. PRESENCE OF THE CYP2B6 516G} T POLYMORPHISM, INCREASED PLASMA EFAVIRENZ CONCENTRATIONS AND EARLY NEUROPSYCHIATRIC SIDE EFFECTS IN SOUTH AFRICAN HIV-INFECTED PATIENTS. AIDS RESEARCH AND THERAPY. 2010;7 (32):1 TO 9",,,,,Y,,,20161123,,OT,ZA,ZA,Efavirenz,Drug level above therapeutic;Virologic failure,129673471,OT,,,,,,,,,129673471,1,HIV infection
12967353,129673531,1,I,,20161110,20161123,20161123,EXP,,ZA-CIPLA LTD.-2016ZA21411,CIPLA,"GOUNDEN V, VAN NIEKERK C, SNYMAN T, GEORGE JA. PRESENCE OF THE CYP2B6 516G} T POLYMORPHISM, INCREASED PLASMA EFAVIRENZ CONCENTRATIONS AND EARLY NEUROPSYCHIATRIC SIDE EFFECTS IN SOUTH AFRICAN HIV-INFECTED PATIENTS. AIDS RESEARCH AND THERAPY. 2010;7 (32):1 TO 9",,,,,Y,,,20161123,,OT,ZA,ZA,Efavirenz,Drug level above therapeutic;Virologic failure,129673531,OT,,,,,,,,,129673531,1,HIV infection
12967355,129673551,1,I,,20161110,20161123,20161123,EXP,,ZA-CIPLA LTD.-2016ZA21412,CIPLA,"GOUNDEN V, VAN NIEKERK C, SNYMAN T, GEORGE JA. PRESENCE OF THE CYP2B6 516G-}T POLYMORPHISM, INCREASED PLASMA EFAVIRENZ CONCENTRATIONS AND EARLY NEUROPSYCHIATRIC SIDE EFFECTS IN SOUTH AFRICAN HIV-INFECTED PATIENTS. AIDS RESEARCH AND THERAPY. 2010;7 (32):1 TO 9",,,,,Y,,,20161123,,OT,ZA,ZA,Efavirenz,Drug level above therapeutic;Virologic failure,129673551,OT,,,,,,,,,129673551,1,HIV infection
12968663,129686633,3,F,20160808,20161123,20161123,20161207,EXP,,CI-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-068157,BRISTOL MYERS SQUIBB,,48,YR,,M,Y,65.7,KG,20161207,,OT,CI,CI,EFAVIRENZ,Toxoplasmosis,129686633,HO,,,129686633,1,20160802,,,,129686633,1,Tuberculosis
12970056,129700561,1,I,20161010,20161117,20161123,20161123,EXP,,IT-GILEAD-2016-0244629,GILEAD,,61,YR,A,M,Y,,,20161123,,MD,IT,IT,EFAVIRENZ,Pancytopenia,129700561,OT,,,,,,,,,129700561,1,HIV infection
12973734,129737341,1,I,20161116,20161117,20161124,20161124,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-098830,BRISTOL MYERS SQUIBB,,61,YR,,M,Y,,,20161124,,CN,IT,IT,EFAVIRENZ,Pancytopenia;Transfusion,129737341,OT,,,,,,,,,129737341,1,HIV infection
12974397,129743971,1,I,,20161110,20161125,20161125,EXP,,US-APOTEX-2016AP015022,APOTEX,,56,YR,,F,Y,62,KG,20161125,,OT,US,US,EFAVIRENZ W/EMTRICITABINE/TENOFOVIR DISOPROXI,Acute kidney injury,129743971,HO,,,,,,,,,129743971,1,Hypertension
12975593,129755931,1,I,,20161117,20161125,20161125,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-100018,BRISTOL MYERS SQUIBB,,,,,,Y,,,20161125,,OT,US,US,EFAVIRENZ,Drug interaction,129755931,OT,,,,,,,,,129755931,1,HIV infection
12975656,129756561,1,I,20161106,20161117,20161125,20161125,EXP,,AU-GILEAD-2016-0244540,GILEAD,,53,YR,A,M,Y,74,KG,20161125,,MD,AU,AU,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pilonidal cyst,129756561,HO,,,129756561,1,20110207,,,,129756561,1,HIV infection
12978291,129782914,4,F,20160222,20161207,20161128,20161213,EXP,,LS-JNJFOC-20161121675,JANSSEN,,42,YR,A,M,Y,51,KG,20161213,,MD,LS,LS,EFAVIRENZ,Hypokalaemia;Pancytopenia,129782914,OT,,,129782914,1,2016,20160721,,,129782914,1,Tuberculosis
12978924,129789241,1,I,20161022,,20161125,20161125,DIR,,,FDA-CTU,,72,YR,,M,N,,,20161125,N,PH,US,US,SUSTIVA,Blood cholesterol increased,,,129789241,HP,,,,,,,129789241,1,HIV infection
12979018,129790181,1,I,20161116,20161118,20161128,20161128,EXP,IT-MINISAL02-383838,IT-MYLANLABS-2016M1051019,MYLAN,,,,,,Y,,,20161127,,MD,IT,IT,EFAVIRENZ,Pancytopenia,129790181,OT,,,,,,,,,129790181,1,HIV infection
12984152,129841521,1,I,,20161122,20161129,20161129,EXP,IT-MINISAL02-384097,IT-MYLANLABS-2016M1051531,MYLAN,"MICHELINI Z., GALLUZZO C., PIRILLO M., FRANCISCI D., ANTONI A., VIVARELLI A., ET AL,. HIV-1 DNA DYNAMICS AND VARIATIONS IN HIV-1 DNA PROTEASE AND REVERSE TRANSCRIPTASE SEQUENCES IN MULTIDRUG RESISTANT PATIENTS DURING SUCCESSFUL RALTEGRAVIR- BASED THERAPY. JOURNAL OF MEDICAL VIROLOGY. 2016;88:12:2115-2124",,,,,Y,,,20161129,,OT,IT,IT,EFAVIRENZ,Drug resistance;Viral mutation identified,129841521,OT,,,,,,,,,129841521,1,HIV infection
12984157,129841571,1,I,,20161119,20161129,20161129,EXP,,FR-MYLANLABS-2016M1051559,MYLAN,"ZUCMAN D, SENE T, HILLAIRE S, KAHN J-E, FARFOUR E, PEYTAVIN G. ANTIHEPATITIS C VIRUS TREATMENTS FOR HIV-HEPATITIS C VIRUS COINFECTED CIRRHOTIC PATIENTS: A NEED TO LOOK BEYOND THE SUSTAINED VIRAL RESPONSE. AIDS 2015;29(14):1903-1904.",,,,,Y,,,20161129,,OT,FR,FR,EFAVIRENZ,Chronic hepatic failure;Drug interaction;Gastrointestinal haemorrhage;Hepatic encephalopathy;Portal venous system anomaly;Renal failure;Renal impairment,129841571,HO,,,,,,,,,129841571,1,HIV infection
12984710,129847101,1,I,,20161123,20161129,20161129,EXP,,AU-ABBVIE-16P-008-1793297-00,ABBVIE,,,,,M,Y,,,20161129,,CN,AU,AU,EFAVIRENZ,Progressive multifocal leukoencephalopathy,129847101,OT,,,,,,,,,129847101,1,Product used for unknown indication
12985056,129850561,1,I,,20161114,20161129,20161129,EXP,,CA-APOTEX-2016AP014805,APOTEX,,52,YR,,M,Y,,,20161129,,CN,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,129850561,OT,,,,,,,,,129850561,1,HIV infection
12987764,129877641,1,I,2013,20161118,20161130,20161130,EXP,,ZA-BAYER-2016-224904,BAYER,MOUTON J P; MEHTA U; PARRISH A G; WILSON D P K; STEWART A; NJUGUNA C W; ET.AL.. MORTALITY FROM ADVERSE DRUG REACTIONS IN ADULT MEDICAL INPATIENTS AT FOUR HOSPITALS IN SOUTH AFRICA: A CROSS-SECTIONAL SURVEY.. BR.J.CLIN.PHARMACOL. 2016;80 (4):818-26,39,YR,A,M,Y,,,20161130,,MD,ZA,ZA,EFAVIRENZ,Hypovolaemic shock,129877641,DE,,,129877641,1,2013,2013,,,129877641,2,Antiretroviral therapy
12988143,129881432,2,F,,20161130,20161130,20161207,EXP,,IT-ABBVIE-16P-083-1793685-00,ABBVIE,,,,,M,Y,,,20161207,,MD,IT,IT,EFAVIRENZ,Cytomegalovirus infection;Hepatitis C;Hepatocellular carcinoma;Herpes zoster;Hypertension;Neuropsychiatric symptoms;Ophthalmic herpes simplex;Renal failure;Transaminases increased,129881432,OT,,,129881432,1,20081016,,,,129881432,1,HIV infection
12988432,129884321,1,I,20160828,20161117,20161130,20161130,EXP,,ZA-GILEAD-2016-0244554,GILEAD,,54,YR,A,F,Y,100.2,KG,20161130,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Gastroenteritis,129884321,HO,,,129884321,1,20140312,201606,,,129884321,1,HIV infection
12989435,129894351,1,I,,20161121,20161201,20161201,EXP,,US-CIPLA LTD.-2016TH22260,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W, ET.AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201,,OT,US,TH,Efavirenz,Liver disorder,129894351,OT,,,,,,,,,129894351,1,HIV infection
12989454,129894541,1,I,,20161121,20161201,20161201,EXP,,US-CIPLA LTD.-2016TH22261,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W, ET.AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201,,OT,US,TH,Efavirenz,Pneumonia,129894541,OT,,,,,,,,,129894541,1,HIV infection
12989455,129894551,1,I,,20161121,20161201,20161201,EXP,,TH-CIPLA LTD.-2016TH22263,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W ET AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201,,OT,TH,TH,Efavirenz,Death,129894551,DE,,,,,,,,,129894551,1,HIV infection
12989538,129895381,1,I,,20161121,20161201,20161201,EXP,,US-CIPLA LTD.-2016TH22303,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W, ET.AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201,,OT,US,TH,Efavirenz,Liver disorder,129895381,OT,,,,,,,,,129895381,1,HIV infection
12989542,129895421,1,I,,20161121,20161201,20161201,EXP,,TH-CIPLA LTD.-2016TH22322,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W ET AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201,,OT,TH,TH,Efavirenz,Death,129895421,DE,,,,,,,,,129895421,1,HIV infection
12989546,129895461,1,I,,20161121,20161201,20161201,EXP,,TH-CIPLA LTD.-2016TH22321,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W ET AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201,,OT,TH,TH,Efavirenz,Death,129895461,DE,,,,,,,,,129895461,1,HIV infection
12989559,129895591,1,I,,20161121,20161201,20161201,EXP,,TH-CIPLA LTD.-2016TH22320,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W ET AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201,,OT,TH,TH,Efavirenz,Death,129895591,DE,,,,,,,,,129895591,1,HIV infection
12989594,129895941,1,I,,20161121,20161201,20161201,EXP,,US-CIPLA LTD.-2016TH22308,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W, ET.AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201,,OT,US,TH,Efavirenz,Pneumonia,129895941,OT,,,,,,,,,129895941,1,HIV infection
12989602,129896021,1,I,,20161121,20161201,20161201,EXP,,US-CIPLA LTD.-2016TH22307,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W, ET.AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201,,OT,US,TH,Efavirenz,Pneumonia,129896021,OT,,,,,,,,,129896021,1,HIV infection
12989612,129896121,1,I,,20161121,20161201,20161201,EXP,,US-CIPLA LTD.-2016TH22306,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W, ET.AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201,,OT,US,TH,Efavirenz,Pneumonia,129896121,OT,,,,,,,,,129896121,1,HIV infection
12989620,129896201,1,I,,20161121,20161201,20161201,EXP,,US-CIPLA LTD.-2016TH22305,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W, ET.AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201,,OT,US,TH,Efavirenz,Liver disorder,129896201,OT,,,,,,,,,129896201,1,HIV infection
12989636,129896361,1,I,,20161121,20161201,20161201,EXP,,US-CIPLA LTD.-2016TH22304,CIPLA,"VARMA JK, NATENIYOM S, AKKSILP S, MANKATITTHAM W, SIRINAK C, SATTAYAWUTHIPONG W, ET.AL.,. HIV CARE AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED SURVIVAL DURING TB TREATMENT IN THAILAND: AN OBSERVATIONAL STUDY. BMC INFECTIOUS DISEASES. 2009;9 (42):1 TO 9",,,,,Y,,,20161201,,OT,US,TH,Efavirenz,Liver disorder,129896361,OT,,,,,,,,,129896361,1,HIV infection
12991318,129913181,1,I,,20161124,20161201,20161201,EXP,IT-MINISAL02-384623,IT-MYLANLABS-2016M1051904,MYLAN,,,,,,Y,,,20161201,,MD,IT,IT,EFAVIRENZ,Cytomegalovirus infection;Hepatocellular carcinoma;Herpes zoster;Hypertension;Neuropsychiatric symptoms;Ophthalmic herpes simplex;Renal failure;Transaminases increased,129913181,OT,,,129913181,1,20081016,,,,129913181,1,Acute HIV infection
12992052,129920522,2,F,20160916,20161123,20161201,20161202,EXP,,KE-GILEAD-2016-0246137,GILEAD,,32,YR,A,F,Y,,,20161202,,OT,KE,KE,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug resistance;Immune reconstitution inflammatory syndrome associated tuberculosis;Oral candidiasis;Virologic failure,129920522,HO,,,129920522,1,20160211,201610,,,129920522,1,Kaposi's sarcoma AIDS related
12992055,129920551,1,I,201611,20161123,20161201,20161201,EXP,,GB-GILEAD-2016-0245557,GILEAD,,58,YR,,M,Y,,,20161201,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,129920551,OT,,,,,,,,,129920551,1,Product used for unknown indication
12992077,129920771,1,I,2009,20161123,20161201,20161201,EXP,,US-GILEAD-2016-0246064,GILEAD,,66,YR,E,M,Y,,,20161201,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Deafness;Hodgkin's disease,129920771,OT,,,,,,,,,129920771,1,HIV infection
12992905,129929051,1,I,19990929,20030128,20161202,20161202,EXP,,AU-CLINIGEN GROUP PLC/ CLINIGEN HEALTHCARE LTD-E2B_00005687,CLINIGEN,,43,YR,,M,Y,71,KG,20161201,,MD,AU,AU,EFAVIRENZ,Acute kidney injury;Hydroureter;Nephrolithiasis,129929051,OT,,,129929051,1,19990907,19990927,,,129929051,1,Product used for unknown indication
12997222,129972221,1,I,,20161122,20161205,20161205,EXP,,FR-CIPLA LTD.-2016FR22268,CIPLA,"MOLINA JM, CAHN P, GRINSZTEJN B, LAZZARIN A, MILLS A, SAAG M ET.AL. RILPIVIRINE VERSUS EFAVIRENZ WITH TENOFOVIR AND EMTRICITABINE IN TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 (ECHO): A PHASE 3 RANDOMISED DOUBLE-BLIND ACTIVE-CONTROLLED TRIAL. LANCET. 2011;378:238 TO 246",,,,,Y,,,20161205,,OT,FR,FR,Efavirenz,Virologic failure,129972221,OT,,,,,,,,,129972221,1,HIV infection
12997245,129972451,1,I,,20161122,20161205,20161205,EXP,,FR-CIPLA LTD.-2016FR22280,CIPLA,"MOLINA JM, CAHN P, GRINSZTEJN B, LAZZARIN A, MILLS A, SAAG M, ET.AL.,. RILPIVIRINE VERSUS EFAVIRENZ WITH TENOFOVIR AND EMTRICITABINE IN TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 (ECHO): A PHASE 3 RANDOMISED DOUBLE-BLIND ACTIVE-CONTROLLED TRIAL. LANCET. 2011;378:238 TO 246",,,,,Y,,,20161205,,OT,FR,FR,EFAVIRENZ PLACEBO;Efavirenz,Hypophosphataemia,129972451,OT,,,,,,,,,129972451,1,HIV infection
12997320,129973201,1,I,,20161122,20161205,20161205,EXP,,FR-CIPLA LTD.-2016FR22402,CIPLA,"MOLINA JM, CAHN P, GRINSZTEJN B, LAZZARIN A, MILLS A, SAAG M, ET.AL.,. RILPIVIRINE VERSUS EFAVIRENZ WITH TENOFOVIR AND EMTRICITABINE IN TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 (ECHO): A PHASE 3 RANDOMISED DOUBLE-BLIND ACTIVE-CONTROLLED TRIAL. LANCET. 2011;378:238 TO 246",,,,,Y,,,20161205,,OT,FR,FR,EFAVIRENZ PLACEBO;Efavirenz,Hypophosphataemia,129973201,OT,,,,,,,,,129973201,1,HIV infection
12997334,129973341,1,I,,20161122,20161205,20161205,EXP,,FR-CIPLA LTD.-2016FR22401,CIPLA,"MOLINA JM, CAHN P, GRINSZTEJN B, LAZZARIN A, MILLS A, SAAG M, ET.AL.,. RILPIVIRINE VERSUS EFAVIRENZ WITH TENOFOVIR AND EMTRICITABINE IN TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 (ECHO): A PHASE 3 RANDOMISED DOUBLE-BLIND ACTIVE-CONTROLLED TRIAL. LANCET. 2011;378:238 TO 246",,,,,Y,,,20161205,,OT,FR,FR,EFAVIRENZ PLACEBO;Efavirenz,Hypophosphataemia,129973341,OT,,,,,,,,,129973341,1,HIV infection
12997341,129973411,1,I,,20161122,20161205,20161205,EXP,,FR-CIPLA LTD.-2016FR22392,CIPLA,"MOLINA JM, CAHN P, GRINSZTEJN B, LAZZARIN A, MILLS A, SAAG M ET.AL. RILPIVIRINE VERSUS EFAVIRENZ WITH TENOFOVIR AND EMTRICITABINE IN TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 (ECHO): A PHASE 3 RANDOMISED DOUBLE-BLIND ACTIVE-CONTROLLED TRIAL. LANCET. 2011;378:238 TO 246",,,,,Y,,,20161205,,OT,FR,FR,Efavirenz,Virologic failure,129973411,OT,,,,,,,,,129973411,1,HIV infection
12997345,129973451,1,I,,20161122,20161205,20161205,EXP,,FR-CIPLA LTD.-2016FR22390,CIPLA,"MOLINA JM, CAHN P, GRINSZTEJN B, LAZZARIN A, MILLS A, SAAG M ET.AL. RILPIVIRINE VERSUS EFAVIRENZ WITH TENOFOVIR AND EMTRICITABINE IN TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 (ECHO): A PHASE 3 RANDOMISED DOUBLE-BLIND ACTIVE-CONTROLLED TRIAL. LANCET. 2011;378:238 TO 246",,,,,Y,,,20161205,,OT,FR,FR,Efavirenz,Virologic failure,129973451,OT,,,,,,,,,129973451,1,HIV infection
12997346,129973461,1,I,,20161122,20161205,20161205,EXP,,FR-CIPLA LTD.-2016FR22391,CIPLA,"MOLINA JM, CAHN P, GRINSZTEJN B, LAZZARIN A, MILLS A, SAAG M ET.AL. RILPIVIRINE VERSUS EFAVIRENZ WITH TENOFOVIR AND EMTRICITABINE IN TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 (ECHO): A PHASE 3 RANDOMISED DOUBLE-BLIND ACTIVE-CONTROLLED TRIAL. LANCET. 2011;378:238 TO 246",,,,,Y,,,20161205,,OT,FR,FR,Efavirenz,Virologic failure,129973461,OT,,,,,,,,,129973461,1,HIV infection
12997350,129973501,1,I,,20161122,20161205,20161205,EXP,,FR-CIPLA LTD.-2016FR22400,CIPLA,"MOLINA JM, CAHN P, GRINSZTEJN B, LAZZARIN A, MILLS A, SAAG M, ET.AL.,. RILPIVIRINE VERSUS EFAVIRENZ WITH TENOFOVIR AND EMTRICITABINE IN TREATMENT-NAIVE ADULTS INFECTED WITH HIV-1 (ECHO): A PHASE 3 RANDOMISED DOUBLE-BLIND ACTIVE-CONTROLLED TRIAL. LANCET. 2011;378:238 TO 246",,,,,Y,,,20161205,,OT,FR,FR,EFAVIRENZ PLACEBO;Efavirenz,Hypophosphataemia,129973501,OT,,,,,,,,,129973501,1,HIV infection
12997382,129973821,1,I,,20161122,20161205,20161205,EXP,,IT-CIPLA LTD.-2016IT22342,CIPLA,"MOFENSON LM, BAGGALEY RC AND MAMELETZIS I.. TENOFOVIR DISOPROXIL FUMARATE SAFETY FOR WOMEN AND THEIR INFANTS DURING PREGNANCY AND BREASTFEEDING: SYSTEMATIC REVIEW. AIDS. 2016",,,,,Y,,,20161205,,MD,US,IT,Efavirenz,Foetal exposure during pregnancy;Talipes,129973821,CA,,,,,,,,,129973821,1,HIV infection
12997393,129973931,1,I,,20161122,20161205,20161205,EXP,,IT-CIPLA LTD.-2016IT22345,CIPLA,"MOFENSON LM, BAGGALEY RC, MAMELETZIS I. TENOFOVIR DISOPROXIL FUMARATE SAFETY FOR WOMEN AND THEIR INFANTS DURING PREGNANCY AND BREASTFEEDING: SYSTEMATIC REVIEW. AIDS. 2016",,,,,Y,,,20161205,,MD,US,IT,Efavirenz,Cryptorchism;Foetal exposure during pregnancy,129973931,CA,,,,,,,,,129973931,1,HIV infection
12999941,129999412,2,F,2016,20161206,20161205,20161215,EXP,,ZA-GILEAD-2016-0246391,GILEAD,,39,YR,A,F,Y,,,20161215,,OT,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion induced;Benign hydatidiform mole;Maternal exposure during pregnancy,129999412,OT,,,129999412,1,20140212,,,,129999412,1,HIV infection
12999969,129999692,2,F,20160920,20161205,20161205,20161215,EXP,,ZW-GILEAD-2016-0246007,GILEAD,,35,YR,A,M,Y,48,KG,20161215,,OT,ZW,ZW,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Meningitis cryptococcal,129999692,DE,,,129999692,1,20160617,20160906,,,129999692,1,Kaposi's sarcoma AIDS related
13000317,130003171,1,I,,20151118,20161206,20161206,EXP,,GB-HETERO LABS LTD-1060445,HETERO,,33,YR,,F,Y,,,20161206,,CN,GB,GB,Efavirenz,Maternal exposure during pregnancy;Normal newborn;Pregnancy with implant contraceptive,130003171,OT,,,,,,,,,130003171,1,HIV infection
13003261,130032611,1,I,20161104,20161201,20161206,20161206,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-103863,BRISTOL MYERS SQUIBB,,42,YR,,M,Y,68,KG,20161206,,OT,IT,IT,EFAVIRENZ,Nephrolithiasis,130032611,OT,,,130032611,3,20161012,,,,130032611,1,HIV infection
13004261,130042612,2,F,,20161129,20161206,20161206,EXP,,AR-STRIDES ARCOLAB LIMITED-2016SP018650,STRIDES,,,,,,Y,,,20161207,,OT,AR,AR,EFAVIRENZ,Foetal exposure during pregnancy;Low birth weight baby,130042612,OT,,,,,,,,,,,
13004508,130045081,1,I,,20161124,20161207,20161207,EXP,,FR-CIPLA LTD.-2016FR22715,CIPLA,"MOFENSON LM, BAGGALEY RC, MAMELETZIS I. TENOFOVIR DISOPROXIL FUMARATE SAFETY FOR WOMEN AND THEIR INFANTS DURING PREGNANCY AND BREASTFEEDING: SYSTEMATIC REVIEW. 2016",,,,,Y,,,20161207,,OT,US,FR,Efavirenz,Cerebral ventricle dilatation;Foetal exposure during pregnancy;White matter lesion,130045081,CA,,,,,,,,,,,
13004665,130046651,1,I,,20161124,20161207,20161207,EXP,,UG-CIPLA LTD.-2016UG22472,CIPLA,"MUKONZO JK, OWEN JS, OGWAL-OKENG J, KUTEESA RB, NANZIGU S, SEWANKAMBO N, ET AL.,. PHARMACOGENETIC-BASED EFAVIRENZ DOSE MODIFICATION: SUGGESTIONS FOR AN AFRICAN POPULATION AND THE DIFFERENT CYP2B6 GENOTYPES. PLOS ONE. 2014;9 (1):1 TO 8",,,,,Y,,,20161207,,OT,UG,UG,Efavirenz,Virologic failure,130046651,OT,,,,,,,,,130046651,1,HIV infection
13004679,130046791,1,I,,20161124,20161207,20161207,EXP,,US-CIPLA LTD.-2016US22403,CIPLA,"LOWENHAUPT EA, MATSON K, QUREISHI B, SAITOH A, PUGATCH D. PSYCHOSIS IN A 12-YEAR-OLD HIV-POSITIVE GIRL WITH AN INCREASED SERUM CONCENTRATION OF EFAVIRENZ. CLINICAL INFECTIOUS DISEASES. 2007;45:E128 TO E130",,,,,Y,,,20161207,,OT,US,US,Efavirenz,Drug level increased;Psychotic disorder;Weight increased,130046791,HO,,,130046791,2,200304,,,,130046791,1,HIV infection
13004683,130046831,1,I,,20161124,20161207,20161207,EXP,,UG-CIPLA LTD.-2016UG22477,CIPLA,"MUKONZO JK, OWEN JS, OGWAL-OKENG J, KUTEESA RB, NANZIGU S, SEWANKAMBO N, ET.AL,. PHARMACOGENETIC-BASED EFAVIRENZ DOSE MODIFICATION: SUGGESTIONS FOR AN AFRICAN POPULATION AND THE DIFFERENT CYP2B6 GENOTYPES. PLOS ONE. 2014;9 (1):1 TO 8",,,,,Y,,,20161207,,OT,UG,UG,Efavirenz,Virologic failure,130046831,OT,,,,,,,,,130046831,1,HIV infection
13004688,130046881,1,I,,20161124,20161207,20161207,EXP,,UG-CIPLA LTD.-2016UG22475,CIPLA,"MUKONZO JK, OWEN JS, OGWAL-OKENG J, KUTEESA RB, NANZIGU S, SEWANKAMBO N, ET.AL.,. PHARMACOGENETIC-BASED EFAVIRENZ DOSE MODIFICATION: SUGGESTIONS FOR AN AFRICAN POPULATION AND THE DIFFERENT CYP2B6 GENOTYPES. PLOS ONE. 2014;9 (1):1 TO 8",,,,,Y,,,20161207,,OT,UG,UG,Efavirenz,Virologic failure,130046881,OT,,,,,,,,,130046881,1,HIV infection
13004691,130046911,1,I,,20161124,20161207,20161207,EXP,,UG-CIPLA LTD.-2016UG22476,CIPLA,"MUKONZO JK, OWEN JS, OGWAL-OKENG J, KUTEESA RB, NANZIGU S, SEWANKAMBO N, ET.AL,. PHARMACOGENETIC-BASED EFAVIRENZ DOSE MODIFICATION: SUGGESTIONS FOR AN AFRICAN POPULATION AND THE DIFFERENT CYP2B6 GENOTYPES. PLOS ONE. 2014;9 (1):1 TO 8",,,,,Y,,,20161207,,OT,UG,UG,Efavirenz,Virologic failure,130046911,OT,,,,,,,,,130046911,1,HIV infection
13004696,130046961,1,I,,20161124,20161207,20161207,EXP,,UG-CIPLA LTD.-2016UG22474,CIPLA,"MUKONZO JK, OWEN JS, OGWAL-OKENG J, KUTEESA RB, NANZIGU S, SEWANKAMBO N, ET AL.,. PHARMACOGENETIC-BASED EFAVIRENZ DOSE MODIFICATION: SUGGESTIONS FOR AN AFRICAN POPULATION AND THE DIFFERENT CYP2B6 GENOTYPES. PLOS ONE. 2014;9 (1):1 TO 8",,,,,Y,,,20161207,,OT,UG,UG,Efavirenz,Virologic failure,130046961,OT,,,,,,,,,130046961,1,HIV infection
13004700,130047001,1,I,,20161124,20161207,20161207,EXP,,UG-CIPLA LTD.-2016UG22473,CIPLA,"MUKONZO JK, OWEN JS, OGWAL-OKENG J, KUTEESA RB, NANZIGU S, SEWANKAMBO N ET AL.,. PHARMACOGENETIC-BASED EFAVIRENZ DOSE MODIFICATION: SUGGESTIONS FOR AN AFRICAN POPULATION AND THE DIFFERENT CYP2B6 GENOTYPES. PLOS ONE. 2014;9(1):1 TO 8",,,,,Y,,,20161207,,OT,UG,UG,Efavirenz,Virologic failure,130047001,OT,,,,,,,,,130047001,1,HIV infection
13004962,130049621,1,I,,20161123,20161207,20161207,EXP,,NG-STRIDES ARCOLAB LIMITED-2016SP019183,STRIDES,,,,,,Y,,,20161207,,CN,NG,NG,EFAVIRENZ,Cleft palate;Foetal exposure during pregnancy,130049621,CA,,,,,,,,,,,
13005210,130052101,1,I,,20161123,20161207,20161207,EXP,,NG-STRIDES ARCOLAB LIMITED-2016SP019187,STRIDES,,,,,,Y,,,20161207,,CN,NG,NG,EFAVIRENZ,Cleft palate;Deafness bilateral;Foetal exposure during pregnancy;Premature baby,130052101,OT,,,,,,,,,,,
13005738,130057381,1,I,,20161124,20161207,20161207,EXP,,US-DRREDDYS-USA/USA/16/0085156,DR REDDYS,"BUNNELL K, VIBHAKAR S, GLOWACKI R, GALLAGHER M, OSEI A, HUHN G. NEPHROTOXICITY ASSOCIATED WITH CONCOMITANT USE OF LEDIPASVIR-SOFOSBUVIR AND TENOFOVIR IN A PATIENT WITH HEPATITIS C VIRUS AND HUMAN IMMUNODEFICIENCY VIRUS COINFECTION. PHARMACOTHERAPY. 2016;36(9):E148-53.",56,YR,,F,Y,62,KG,20161207,,OT,COUNTRY NOT SPECIFIED,US,efavirenz,Acute kidney injury;Dizziness;Drug interaction;Electrocardiogram T wave inversion;Fall;Metabolic acidosis;Renal tubular necrosis;Tubulointerstitial nephritis,130057381,HO,,,,,,,,,130057381,1,Product used for unknown indication
13007665,130076651,1,I,,20161201,20161207,20161207,EXP,,US-GILEAD-2016-0247283,GILEAD,,24,YR,A,M,Y,,,20161207,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Anger;Anxiety;Fatigue;Haematemesis;Haematochezia;Lipoatrophy;Major depression;Malaise;Muscle atrophy;Sensation of foreign body;Vomiting;Weight decreased,130076651,OT,,,,,,,,,130076651,1,HIV infection
13008100,130081001,1,I,,20161124,20161208,20161208,EXP,,FR-CIPLA LTD.-2016FR22834,CIPLA,"MOFENSON LM, BAGGALEY RC, MAMELETZIS I. TENOFOVIR DISOPROXIL FUMARATE SAFETY FOR WOMEN AND THEIR INFANTS DURING PREGNANCY AND BREASTFEEDING: SYSTEMATIC REVIEW. 2016",,,,,Y,,,20161208,,OT,US,FR,Efavirenz,Foetal exposure during pregnancy;Pachygyria,130081001,CA,,,,,,,,,,,
13008101,130081011,1,I,,20161124,20161208,20161208,EXP,,FR-CIPLA LTD.-2016FR22833,CIPLA,"MOFENSON LM, BAGGALEY RC, MAMELETZIS I. TENOFOVIR DISOPROXIL FUMARATE SAFETY FOR WOMEN AND THEIR INFANTS DURING PREGNANCY AND BREASTFEEDING: SYSTEMATIC REVIEW. 2016",,,,,Y,,,20161208,,OT,US,FR,Efavirenz,Congenital cerebral cyst;Foetal exposure during pregnancy,130081011,CA,,,,,,,,,,,
13008102,130081021,1,I,,20161124,20161208,20161208,EXP,,FR-CIPLA LTD.-2016FR22832,CIPLA,"MOFENSON LM, BAGGALEY RC, MAMELETZIS I. TENOFOVIR DISOPROXIL FUMARATE SAFETY FOR WOMEN AND THEIR INFANTS DURING PREGNANCY AND BREASTFEEDING: SYSTEMATIC REVIEW. 2016",,,,,Y,,,20161208,,OT,US,FR,Efavirenz,Congenital central nervous system anomaly;Foetal exposure during pregnancy,130081021,CA,,,,,,,,,,,
13008276,130082761,1,I,,20161123,20161208,20161208,EXP,,IN-SUN PHARMACEUTICAL INDUSTRIES LTD-2016US-128841,RANBAXY,,9,YR,,F,Y,12,KG,20161208,,OT,GB,IN,Efavirenz,Subdural haematoma,130082761,OT,,,,,,,,,130082761,1,Cerebral infarction
13008521,130085211,1,I,,20161124,20161208,20161208,EXP,,US-AUROBINDO-AUR-APL-2016-15208,AUROBINDO,,66,YR,,M,Y,,,20161208,,MD,US,US,EFAVIRENZ,Retinal degeneration;Retinal toxicity,130085211,OT,,,,,,,,,130085211,1,HIV infection
13009134,130091341,1,I,,20161201,20161208,20161208,EXP,,US-GILEAD-2016-0247521,GILEAD,,43,YR,A,M,Y,,,20161208,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cerebrovascular accident;Hemiplegia,130091341,OT,,,,,,,,,130091341,1,Product used for unknown indication
13010853,130108531,1,I,,20161130,20161208,20161208,EXP,,ZA-MYLANLABS-2016M1053403,MYLAN,"VARIAVA E, SIGAUKE FR, MUCHICHWA P, MAARTENS G, MARTINSON N. EFAVIRENZ TOXICITY MANIFESTING AS CEREBELLAR ATAXIA: CASE SERIES FROM SOUTH AFRICA. TOP-ANTIVIR-MED 2016;24(1):412.",,,,,Y,,,20161208,,OT,ZA,ZA,EFAVIRENZ,Anticonvulsant drug level increased;Cerebellar ataxia;Toxicity to various agents,130108531,HO,,,,,,,,,130108531,1,HIV infection
13013656,130136561,1,I,,20161202,20161209,20161209,EXP,,US-SCIEGEN PHARMACEUTICALS INC-2016SCILIT00610,SCIEGEN,,56,YR,,F,Y,,,20161209,,OT,US,US,Efavirenz,Acute kidney injury;Asthenia;Dizziness;Fall;Hepatic cirrhosis;Hypokalaemia;Metabolic acidosis;Proteinuria;Pyuria;Renal tubular necrosis;Tubulointerstitial nephritis,130136561,HO,,,,,,,,,130136561,1,Hypertension
13013727,130137271,1,I,20160813,20161201,20161209,20161209,EXP,,US-GILEAD-2016-0247321,GILEAD,,63,YR,A,M,Y,79,KG,20161209,,MD,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Syncope,130137271,HO,,,130137271,1,20100704,,,,130137271,1,HIV infection
13014029,130140291,1,I,,20161205,20161209,20161209,EXP,,GB-GILEAD-2016-0247859,GILEAD,,65,YR,E,M,Y,,,20161209,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,130140291,DE,,,,,,,,,130140291,1,HIV infection
13014250,130142501,1,I,,20161128,20161209,20161209,EXP,,FR-TEVA-718046ISR,TEVA,"ZUCMAN D, SENE T, HILLAIRE S, KAHN J-E, FARFOUR E, PEYTAVIN G. ANTIHEPATITIS C VIRUS TREATMENTS FOR HIV-HEPATITIS C VIRUS COINFECTED CIRRHOTIC PATIENTS: A NEED TO LOOK BEYOND THE SUSTAINED VIRAL RESPONSE. AIDS 2015;29(14):1903-1904.",,,A,M,Y,,,20161209,,OT,FR,FR,efavirenz,Chronic hepatic failure;Drug interaction;Gastrointestinal haemorrhage;Hepatic encephalopathy;Renal failure;Renal impairment;Venous injury,130142501,OT,,,,,,,,,130142501,1,HIV infection
13014538,130145382,2,F,,20161215,20161209,20161222,EXP,,PHHY2015BR064616,NOVARTIS,,,,,F,Y,50,KG,20161222,,MD,BR,BR,EFAVIRENZ,Alopecia;Blood iron increased;Dizziness;Drug intolerance;Haemoglobin abnormal;Inappropriate schedule of drug administration;Nausea;Poisoning;Serum ferritin abnormal;Serum ferritin decreased;Serum ferritin increased;Vomiting;Weight increased;Wrong technique in product usage process,130145382,OT,,,,,,,,,130145382,1,Haemoglobinopathy
13014614,130146141,1,I,20161130,20161205,20161209,20161209,EXP,,GB-GILEAD-2016-0247766,GILEAD,,48,YR,A,M,Y,,,20161209,,CN,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,130146141,DE,,,,,,,,,130146141,1,HIV infection
13016903,130169032,2,F,,20161202,20161212,20161216,EXP,,US-AUROBINDO-AUR-APL-2016-15038,AUROBINDO,,56,YR,,F,Y,,,20161216,,OT,US,US,EFAVIRENZ W/EMTRICITABINE/TENOFOVIR DISOPROXI,Acute kidney injury;Asthenia;Dizziness;Fall;Hypokalaemia;Labelled drug-drug interaction medication error;Renal tubular necrosis;Tubulointerstitial nephritis,130169032,HO,,,,,,,,,130169032,1,Hypertension
13020118,130201181,1,I,,20161205,20161212,20161212,EXP,,US-GILEAD-2016-0248150,GILEAD,,52,YR,A,M,Y,,,20161212,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cardiac assistance device user,130201181,OT,,,,,,,,,130201181,1,HIV infection
13020370,130203701,1,I,20161104,20161201,20161212,20161212,EXP,,IT-GILEAD-2016-0248192,GILEAD,,42,YR,A,M,Y,68,KG,20161212,,MD,IT,IT,EFAVIRENZ,Nephrolithiasis,130203701,OT,,,130203701,1,20161012,,,,130203701,1,Product used for unknown indication
13020678,130206781,1,I,,20161207,20161212,20161212,EXP,,US-GILEAD-2016-0247902,GILEAD,,56,YR,A,F,Y,,,20161212,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Concussion;Fall;Haemorrhage;Rectal prolapse;Rib fracture;Upper limb fracture;Weight decreased,130206781,HO,,,,,,,,,130206781,1,Product used for unknown indication
13020961,130209611,1,I,,20161202,20161212,20161212,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-104130,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20161212,,PH,FR,FR,SUSTIVA,Dysphagia;Gastrointestinal tube insertion,130209611,OT,,,,,,,,,130209611,1,Product used for unknown indication
13024548,130245481,1,I,2016,20161207,20161213,20161213,EXP,,GB-GILEAD-2016-0248055,GILEAD,,65,YR,E,M,Y,,,20161213,,OT,GB,GB,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Death,130245481,OT,,,,,,,,,130245481,1,Product used for unknown indication
13038747,130387471,1,I,,20161205,20161219,20161219,EXP,,ZA-HETERO LABS LTD-1060959,HETERO,"VARIAVA E, SIGAUKE FR, MUCHICHWA P, MAARTENS G, MARTINSON N. EFAVIRENZ TOXICITY MANIFESTING AS CEREBELLAR ATAXIA: CASE SERIES FROM SOUTH AFRICA.",,,,F,Y,,,20161219,,OT,ZA,ZA,Efavirenz,Cerebellar ataxia,130387471,OT,,,,,,,,,130387471,1,HIV infection
13039093,130390931,1,I,,20161205,20161219,20161219,EXP,,IT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-104925,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20161219,,MD,IT,IT,SUSTIVA,Hepatic neoplasm,130390931,OT,,,130390931,1,20160628,,,,130390931,1,Hepatitis C virus test
13050898,130508981,1,I,2015,20160401,20161221,20161221,PER,,US-ENDO PHARMACEUTICALS INC.-2016-002624,ENDO,,67,YR,,M,Y,113.5,KG,20161221,,CN,US,US,SUSTIVA,Dementia;Depressed mood;Hypersomnia;Inappropriate schedule of drug administration;Intentional product misuse;Mental disorder;Pain,,,,,130508981,1,20150704,20160316,,,130508981,1,Back pain
13051321,130513211,1,I,,20161214,20161221,20161221,EXP,,ES-MYLANLABS-2016M1056885,MYLAN,"MEDRANO-CASIQUE N, TONG HY, BOROBIA AM, CARCAS AJ, FRIAS J, RAMIREZ E. NON-CHEMOTHERAPY-INDUCED AGRANULOCYTOSIS DETECTED BY A PROSPECTIVE PHARMACOVIGILANCE PROGRAM IN A TERTIARY HOSPITAL. BASIC-CLIN-PHARMACOL-TOXICOL 2015;117(6):399-408.",,,,,Y,,,20161221,,MD,ES,ES,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Agranulocytosis,130513211,HO,,,,,,,,,130513211,1,Pneumonia
13054613,130546132,2,F,,20161222,20161222,20161223,EXP,,IT-009507513-1612ITA011075,MERCK,,,,,,Y,,,20161223,,OT,IT,IT,EFAVIRENZ,Drug resistance;Viral mutation identified,130546132,OT,,,,,,,,,130546132,1,HIV infection
13058291,130582911,1,I,,20161214,20161223,20161223,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-110062,BRISTOL MYERS SQUIBB,,47,YR,,M,Y,,,20161223,,OT,ES,ES,EFAVIRENZ,Agranulocytosis,130582911,DE,,,,,,,,,130582911,1,Product used for unknown indication
13059393,130593931,1,I,20160921,20161215,20161223,20161223,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-108225,BRISTOL MYERS SQUIBB,,52,YR,,F,Y,50,KG,20161223,,CN,CN,CN,EFAVIRENZ,Hepatic function abnormal,130593931,OT,,,130593931,1,20160722,20161014,,,130593931,1,HIV test
13059406,130594061,1,I,20160914,20161220,20161223,20161223,EXP,,UG-GLAXOSMITHKLINE-UG2016GSK189477,GLAXOSMITHKLINE,,23,YR,,F,Y,39.5,KG,20161223,,MD,UG,UG,EFAVIRENZ,Weight decreased,130594061,OT,,,130594061,1,20150104,20160913,,,130594061,1,HIV infection
13059435,130594351,1,I,20160914,20161220,20161223,20161223,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2016GSK189477,VIIV,,23,YR,,F,Y,39.5,KG,20161223,,MD,UG,UG,EFAVIRENZ,Weight decreased,130594351,OT,,,130594351,1,20150104,20160913,,,130594351,1,HIV infection
13059609,130596091,1,I,,20161121,20161223,20161223,EXP,,IT-009507513-1612ITA011364,MERCK,,,,A,,Y,,,20161223,,CN,US,IT,EFAVIRENZ,Drug resistance;Viral mutation identified,130596091,OT,,,,,,,,,130596091,1,HIV infection
13059901,130599011,1,I,201602,20161221,20161223,20161223,EXP,,US-GILEAD-2016-0250181,GILEAD,,62,YR,A,M,Y,,,20161223,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Accident;Surgery,130599011,OT,,,,,,,,,130599011,1,Product used for unknown indication
13061396,130613961,1,I,,20161214,20161226,20161226,EXP,,DE-CIPLA LTD.-2016DE23747,CIPLA,"KROIDL A, ELLO F, MGAYA J, LENNEMANN T, MOH R, MAGANGA L ET AL.,. VIROLOGICAL EFFICACY OF 24-WEEKS FOZIVUDINE BASED REGIMEN IN ART-NAIVE PATIENTS FROM TANZANIA AND COTE D^IVOIRE. AIDS. 2016",,,,,Y,,,20161226,,OT,DE,DE,Efavirenz,Anaemia,130613961,OT,,,,,,,,,130613961,1,HIV infection
13065755,130657551,1,I,,20161220,20161227,20161227,EXP,,IT-VIIV HEALTHCARE LIMITED-IT2016190886,VIIV,,,,A,M,Y,,,20161227,,MD,IT,IT,Efavirenz,Virologic failure,130657551,OT,,,,,,,,,130657551,1,HIV infection
13065833,130658331,1,I,,20161220,20161227,20161227,EXP,,IT-GLAXOSMITHKLINE-IT2016190886,GLAXOSMITHKLINE,,,,A,M,Y,,,20161227,,MD,IT,IT,Efavirenz,Virologic failure,130658331,OT,,,,,,,,,130658331,1,HIV infection
13066539,130665391,1,I,200606,20161018,20161227,20161227,EXP,,GB-JNJFOC-20161100084,JANSSEN,,44,YR,A,M,Y,88,KG,20161227,,MD,GB,GB,EFAVIRENZ,Glomerular filtration rate decreased;Transient ischaemic attack,130665391,OT,,,130665391,1,201209,201401,,,130665391,1,HIV infection
13067654,130676542,2,F,,20161216,20161228,20161228,EXP,,US-CIPLA LTD.-2016US23768,CIPLA,,,,,,Y,,,20161228,,OT,BR,US,Efavirenz,Concomitant disease aggravated;Drug-induced liver injury;Hypersensitivity,130676542,OT,,,,,,,,,130676542,1,HIV infection
13068147,130681472,2,F,20160701,20161221,20161228,20161229,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-109319,BRISTOL MYERS SQUIBB,,,,,,Y,,,20161229,,CN,GB,GB,EFAVIRENZ;EFAVIRENZ AUROBINDO,Macular oedema,130681472,OT,,,130681472,1,201006,201606,,,130681472,1,HIV infection
13069028,130690281,1,I,,20161220,20161228,20161228,EXP,,BE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-110512,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20161228,,OT,BE,BE,EFAVIRENZ,Drug resistance;Viral mutation identified,130690281,OT,,,,,,,,,130690281,1,Antiretroviral therapy
13069029,130690291,1,I,,20161220,20161228,20161228,EXP,,BE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-110539,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20161228,,OT,BE,BE,EFAVIRENZ,Drug resistance;Viral mutation identified,130690291,OT,,,,,,,,,130690291,1,Antiretroviral therapy
13077044,130770441,1,I,20090623,20161221,20161230,20161230,EXP,,IT-SA-2016SA234072,AVENTIS,,31,YR,A,M,Y,,,20161230,,PH,IT,IT,SUSTIVA,Alanine aminotransferase increased;Aspartate aminotransferase increased;Hepatitis;Pancreatitis,130770441,DE,,,130770441,1,20090430,20091106,,,130770441,1,Disseminated tuberculosis
13077519,130775191,1,I,,20161216,20161231,20161231,EXP,,BR-HETERO LABS LTD-1061421,HETERO,,,,,F,Y,1.5,KG,20161231,,OT,BR,BR,Efavirenz\ lamivudine \ Tenofovir  disoproxil fumarate,Foetal exposure during pregnancy;Weight increased,130775191,HO,,,130775191,1,20160831,,,,130775191,1,HIV infection
7155921,715592111,11,F,,20161014,20091022,20161014,EXP,,CA-ROCHE-663583,ROCHE,"PFEFFER G, PFEFFER G, COTE H, MONTANER J, LI C, JITRATKOSOL M AND MEZEI M. OPHTHALMOPLEGIA AND PTOSIS: MITOCHONDRIAL TOXICITY IN PATIENTS RECEIVING HIV THERAPY. NEUROLOGY 2009 JUL 07;73 (1):71-72.",52,YR,,M,Y,,,20161014,,MD,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,715592111,OT,,,,,,,,,715592111,1,HIV infection
